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Targeting the Nt17 domain of the huntingtin protein via natural and chemical 
modifications: impact on aggregation and membrane interactions 
 
Faezeh Sedighi 
Huntington Disease (HD) is a fatal neurodegenerative disorder caused by an expanded 
polyglutamine domain (polyQ) in the first exon of the huntingtin protein (htt-exon1). The major 
hallmark of HD is the accumulation of aggregates into proteinaceous inclusion bodies. PolyQ 
expansion in huntingtin promotes self-assembly into a variety of toxic aggregates such as 
oligomers, fibrils, and amorphous aggregates. The resulting heterogeneous mixture of distinct 
species makes it difficult to assign toxic function to specific aggregate structures. In addition, htt 
interacts with a variety of membranous surfaces. The first 17 amino acids (Nt17) of htt directly 
flanking the polyQ domain functions in binding lipids and in promoting aggregation based on its 
ability to form an amphipathic a-helix. Nt17 undergoes several posttranslational modifications 
that modulate aggregation, subcellular localization, and toxicity of mutant htt. To gain in-depth 
mechanistic insights into huntingtin aggregation at lipid interfaces, both natural and chemical Nt17 
modification strategies were employed. Specifically, the direct impact of SUMOylation was 
characterized. SUMOylation promoted the formation of large, SDS-soluble amorphous aggregates 
of htt and significantly inhibited the ability of htt to bind lipid membranes. In addition, the 
interaction of various htt aggregates species with lipid membrane was determined, and oligomers 
displayed the largest membrane activity. To further investigate these htt oligomers, a crosslinking 
strategy was employed that targeted lysine residues within Nt17. Crosslinking htt oligomers 
compromises their conformational flexibility, inhibiting their membrane activity. Cellular toxicity 
of crosslinked oligomers was also reduced, suggesting membrane activity may underlie 
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1. Protein aggregation and Huntington’s disease  
1.1. Neurodegenerative diseases  
 Neurodegeneration refers to the progressive dysfunction and atrophy of neurons. The 
presence and development of abnormal protein assemblies as various intracellular proteinaceous 
inclusions and extracellular neurotic plaques are the most predominant features of 
neurodegenerative diseases. These deposits impact several areas of the brain, causing memory and 
cognitive impairment. Current therapeutics alleviate the symptoms of neurodegenerative diseases 
and developing effective therapies has been impeded by the limitation of our mechanistic-based 
knowledge of the underlying cause and progression of neurodegeneration.  
1.2. Amyloid formation in neurodegenerative disease  
Several age-related neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's 
(PD), Huntington's diseases (HD), are associated with the accumulation of micron sized insoluble 
proteinaceous deposits in cells and tissues.1–3 These deposits are comprised of a specific protein 
(or proteins) associated specifically with each disease. For example, extracellular plaques of Aβ 
and tangles of tau are connected to (AD); Lewy bodies of α-synuclein are implicated in (PD); and 
nuclear inclusions of a mutant huntingtin (htt) protein are observed in HD. These deposits are 
comprised of elongated filaments termed amyloid, which exhibit a cross β-sheet structure.4,5 While 
amyloid fibrils share this generic β-sheet ultrastructure, a variety of morphologically distinct fibrils 
can form, which is referred to as polymorphism.6–8 Beyond the formation of fibrillar aggregates, 
numerous other aggregate species, some of which are intermediates to fibrils, also form. These 
include small oligomers (dimers, trimers, dodecamers), high molecular weight oligomers, 
protofibrils, amorphous aggregates, and annular aggregates. The large variety of aggregate species 
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involved in the aggregation process has made it challenging to assign toxic functions to specific 
aggregate structures, and identifying potent toxic species continues to be a major goal.  
1.3. Polyglutamine disorders 
  A subset of protein aggregation related neurodegenerative diseases are the CAG repeat or 
polyglutamine (polyQ) disorders. These genetic neurodegenerative disorders are caused by an 
expansion of CAG repeats coding for glutamine, which leads to an expanded polyglutamine tract 
in the translated protein.12,13 A family of at least ten heritable polyQ disorders has been identified, 
(Table 1.1) including Huntington’s disease (HD), the spinocerebellar ataxias, type 1 (SCA-1), type 
2 (SCA-2), type 3 (SCA-3, also known as Machado-Joseph disease), type 6 (SCA-6), type 7 (SCA-
7), Dentatorubropalli-doluysian atrophy (DRPLA) and spinobulbar muscular atrophy (SBMA).14–
21 HD is the most common genetic neurodegenerative disease. While these diseases share some 
common pathological features, the causative genes associated with each subtype are structurally 
and functionally distinct.22,23 The expressed mutant proteins containing expanded polyQ ultimately 
lead to the degeneration of specific neuronal subpopulation in the central nervous system (CNS). 
For each disorder, there is a critical threshold for the length of the polyQ, which once exceeded, is 
directly correlated with the age of pathological onset and severity of the disease.24–27  
 Proteins containing expanded polyQ tract aggregate into detergent-insoluble amyloid-like 
structure. Studies of cellular model of polyQ diseases have revealed correlation between the polyQ 
length and the rate of aggregation.28,29 This aggregation results in the prominent, pathological 
feature associated with polyQ diseases, micron size proteinaceous inclusions.4,5 While the toxicity 
is mostly dependent on the length of the polyQ and protein expression level, the exact correlation 
of protein aggregates and the pathologies is largely unknown. The similarities in the pathogenic 
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process and several shared features of protein aggregation at the cellular and molecular level 
indicate a common toxic gain of function for polyQ-containing proteins.  
Table 1. CAG repeat disorders  
disease common name protein polyQ 
Huntington disease (HD)  huntingtin 36–100 




syndrome atrophin-1 49–88 
spinocerebellar ataxia type 1 (SCA1)  ataxin-1 39–88 
spinocerebellar ataxia type 2 (SCA2)  ataxin-2 33–77 
spinocerebellar ataxia type 3 (SCA3) Machado-Joseph ataxin-3 55–86 
spinocerebellar ataxia type 6 (SCA6)  CACNA1A 21–33 
spinocerebellar ataxia type 7 (SCA7)  ataxin-7 38–120 
spinocerebellar ataxia type 12 (SCA12)  PPP2R2B 66–78 
spinocerebellar ataxia type 17 (SCA17)  TATA-box binding protein 47–63 
 
 Given the biological and clinical overlap among polyQ disorders (and more broadly 
neurodegenerative diseases in general), the therapeutic-based knowledge acquired by a given 
polyQ disorder is informative and possibly applicable to others. So far, there are no disease-
modifying therapies available for polyQ disorders. A current strategy under investigation has 
focused on lowering the expression of the target gene at the mRNA level, thereby effectively 
reducing the level of mutant polyQ related protein.30–33 There is also significant effort into 
understanding the biochemical and biophysical aspects of aggregation of polyQ-containing 
proteins to understand the underlying mode of toxicity in the hope that this will reveal therapeutic 
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targets. High profile clinical trials that target protein aggregation associated with other 
neurodegenerative diseases like AD have failed;34 however, these trials suffered from the necessity 
to enroll late stage patient as early diagnosis is not possible in most neurodegenerative disease. 
Early intervention may be vital for these strategies to be effective. As polyQ disorders are genetic, 
early diagnosis is possible, making early intervention possible. As a result, research into polyQ 
disorders can lead to better clinical trials to test the effectiveness of therapeutic strategies aimed at 
protein aggregation. 
1.4. Huntingtin protein (htt) associated with Huntington’s disease (HD)  
 HD is an autosomal dominant polyQ disorder characterized by involuntary choreiform 
movement, psychiatric manifestation, and progressive dementia.35 The neuropathological change 
of HD includes significant neuronal death within the striatum and subcortical brain structure, and 
to a lesser extent within the cortex.36 The genetic defect causing HD is located in chromosome 4, 
containing substantially increased trinucleotide repeats.21 The polyQ length for individuals with 
normal alleles is shorter than 35; however, 35-39 repeats may induce the phenotypic symptoms, 
40-60 polyQ repeats results in adult onset, and repeats longer than 60 is associated with the juvenile 
type of HD.18,26,27  
 The full length of huntingtin protein (htt) contains 3144 amino acids, resulting in an 
approximately 350 kDa protein. htt is a multifunctional protein playing a critical role in the 
regulation of gene expression,37 vesicle transport,38 and autophagy.39 The first exon of htt (htt-
exon1) contains the polyQ domain, and this fragment (and other similar N-terminal fragments) are 
acutely toxic and recapitulate HD phenotype when expressed in transgenic HD animal models.4,40–
43 As a result, htt-exon1 is the most actively studied htt fragment. Expression of htt-exon1 with an 
expanded polyQ domain is sufficient to develop a broad spectrum of phenotypic symptoms in 
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transgenic mice.45,46 Furthermore, staining of postmortem HD patient’s brain tissue reveals the 
presence of nucleation bodies colocalized with N-terminal fragment of mutant htt.47 In htt-exon1, 
the polyQ domain is flanked by the 17-residue long N-terminal domain (Nt17) and a proline-rich 
domain (PRD) on its C terminal side that contains several polyproline (polyP) stretches (Fig 1.1). 
The primary hallmark of HD is the pronounced accumulation of mutant htt containing expanded 
polyQ into neuronal cytosolic or nuclear inclusions.4 
 
Fig 1.1 The full-length htt protein contains several HEAT repeats. The inset indicates the location of htt 
exon1, with the Nt17, polyQ, and proline-rich domains indicated. 
1.5. Huntingtin forms a variety of aggregate species  
 While extensive research has been conducted toward understanding htt aggregation and 
related toxic gain of function, the precise aggregates involved in HD remains controversial. N-
terminal mutant htt fragments with expanded polyQ aggregate into detergent-insoluble amyloid 
fibrils.4,48–53 Numerous studies using a variety of experimental systems (purified proteins to 
cellular and animal models) established a direct correlation between polyQ length and the 
rate/extent of htt aggregation.54–56 Within a cellular context, htt with longer polyQ tracts form 
nuclear inclusion more efficiently than htt with shorter polyQ.55 These observations are consistent 
with in vitro studies demonstrating that aggregation rates of mutant htt increase with further 
expansion of the polyQ tract.48,51,54 While mutant htt generally aggregates into fibrils,57–59 it also 
forms several other distinct aggregate species, including dimer,60 tetramer,61 spherical or annular 
oligomers54,58,62 as well as amorphous aggregates. Biophysical and biochemical approaches have 
been employed to ascertain which of these aggregate species are on and off the fibril formation 
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pathway. The presence of heterogeneous mixtures of distinct aggregate species make it difficult to 
assign toxic functions to specific aggregate structures.  
 Fibril formation is generally accepted to form via a nucleus-dependent mechanism.9–11 (Fig 
1.2) The reaction initiates with a lag phase, which is the time required for the formation of a 
monomeric or multimeric critical nucleus. Once the nucleus is formed, the reaction is followed by 
an elongation or growth phase characterized by a relatively rapid extension of fibril aggregation. 
The steep transition step proceeds to a flat region known as the plateau phase and represents a 
steady state of the overall conversion of monomers to fibrils. The rate of aggregation is dependent 
on the time required for the formation of a monomeric or multimeric critical nucleus during the 
lag phase. A variety of factors could cause the lag phase to be shortened or ultimately eliminated. 
The addition of preformed fibrillar species to a sample protein under the aggregation condition 
(referred to as seeding process), change in the experimental condition, modification, and mutation 
causing the situation wherein nucleation is no longer a rate-limiting step.  
 
Fig 1.2 Schematic representation of the amyloid aggregation via nucleation-dependent polymerization. Lag 
phase involves transition from non-native protein monomers to prefibrillar oligomers, eventually forming 
a critical nucleus. Upon nucleation, rapid fibrils growth (elongation phase) is observed. The plateau phase 
represents the steady state when maximum fibrils growth has been reached.  
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Despite the complexity of the aggregation mechanism, a wealth of critical biophysical information 
has been accumulated. Several aggregation schemes associated with the formation of fibrils in 
polyQ containing proteins have been proposed (Fig 1.3). Two of the more prominent one is, 1) 
rearrangement of monomers into structures that directly nucleate fibrils formation11,48,49 (Fig 
1.3A), 2) formation of insoluble oligomeric intermediates that can associate into the b-sheet rich 
multimeric nucleus via structural rearrangement leading to the formation of fibrils54,63,64 (Fig 
1.3B). There are also several other off pathways aggregation schemes that can lead to the formation 
of a variety of oligomers, annular or amorphous aggregates (Fig 1.3C). Eventually, all these higher 
order aggregates may accumulate together to form micron-sized inclusion that is the hallmark of 
htt aggregation (Fig 1.3D). 
 Nucleation kinetic analysis of various polyQ peptides revealed a monomeric nucleation 
aggregation model for the longer polyQ, while shorter polyQ length appears to aggregates via a 
tetrameric critical nucleus.11 Adding to the complexity of the aggregation mechanism is the 
detection of transient oligomers prior to fibril elongation, suggesting that both aggregation 
pathways could occur simultaneously. Using AFM imaging techniques, oligomers formed by 
various lengths of polyQ with different levels of stabilities were detected.54 Different 
environmental factors may also affect the appearance of oligomeric species, such as the presence 
of a particular aggregation surface or usage of a specific solvent involved in preparation protocols. 
For example, on the mica surface, oligomeric-mediated fibril formation appeared to be the 
dominant aggregation scheme. The intervention of the environmental factor in the fibril formation 
pathway points to the importance of designing experiments to mechanistically investigate 
aggregation in relevant cellular environment.  
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Fig 1.3 A schematic model for misfolding and aggregation of mutant htt protein. (A) A monomeric critical 
nucleus that leads directly to fibril formation (B) Fibril formation via oligomeric pathway (C) Off pathway 
aggregation routes (D) Inclusion body formation 
1.6. Ambiguity in the toxicity associated with variety of mutant htt species  
1.6.1. Protective role of Inclusion bodies 
 The precise role of different htt aggregates with regard to toxicity is still not clear. 
Immunostaining of postmortem brain tissues of HD patients indicated htt localization to the 
neuronal intranuclear and dystrophic neurite inclusions in both cortex and striatum.47 The micron-
size cytoplastic and intranuclear inclusions have been reported to underlie the neuropathology 
observed in transgenic mouse model of HD.4 However, several observations suggested that the 
sequestration of mutant htt into prominent inclusion bodies is a cell-protective phenomenon.28,65 
Despite the large scale of the striatum compartments being affected in the HD brain, the 
distribution of nuclear aggregates associated with mutant htt in the striatum does not correspond 
to the pathology of HD.66 Whereas neuropil aggregates, with the less common occurrence, may be 
involved in dendritic pathology.66  
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 In cellular models of HD, the presence of inclusion in the nucleus do not correlate with htt 
induced neurodegeneration.28 Toxic species might in fact exist in the diffuse fraction of mutant htt 
rather than inclusion bodies.28,65 That is, the dispersed fraction observed in cells may consist of 
toxic smaller aggregates such as fibrils and oligomers that are invisible to conventional light 
microscopy. The Identification and characterization of species that best predict the neuronal death 
within the diffused fraction of mutant htt in neurons require novel experimental techniques with 
high resolution to visualize species smaller than micron size inclusions. Additionally, approaches 
capable of distinguishing the complex mixtures of aggregates in the cell and correlating this 
information to the pathological outcome needs to be applied. The conflict associated with 
neurotoxicity of inclusions may emerge from the variety of model systems being examined, 
ranging from cultured cells to intact animals or postmortem tissue of HD brain patients. It also 
appears that the location that the inclusions have been found throughout the cells may affect the 
putative risk of neurotoxicity. Depending on the system of study and the locations that inclusions 
are found, they may cause different neurological effects. It is also possible that htt toxicity is 
multifaceted. That is, different aggregate species may be involved with distinct toxic mechanisms 
that are not mutually exclusive. Obtaining toxic assignments to each htt aggregate form could 
potentially provide understanding to the striking cell specificity of htt-mediated toxicity. 
Identification of mutant htt features that drive the emergence of fibrils, oligomers, and other small 
interties, as well as the subsequent molecular event triggering the initial phases of cellular toxicity 
may lead to novel therapeutic strategies. As a result, the factors that modulate htt aggregation 
toward specific aggregate species along with their association with HD pathology have been of 
interest.  
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1.6.2. Fibril-associated toxicity  
 Due to the current ambiguity regarding the toxic species associated with htt mutant 
aggregates, a variety of sensitive techniques like single molecule super resolution fluorescent 
microscopy have recently been applied to investigate the smaller mutant htt aggregates within the 
diffused population. In the cytosolic compartment, small fibrils resembled those fibrils bundles 
detected in vitro were observed that may be linked to neurotoxicity.67,68 A combination of EM and 
immunoreactivity technique has identified fibrillar-like structures in both cell model and HD 
transgenic mice,4,51,69 as well as postmortem brain tissues.47 Interestingly, these fibrillar structures 
are not present in the process of inclusion body formation; rather their emergence occurs at the 
later stage, coinciding with the presence of mature inclusions.57 This suggests that inclusion bodies 
initially form from monomeric and small oligomeric htt species.  
 In terms of toxicity, fibrillar assembly of the htt fragment corresponding to htt-exon1 
trigger apoptotic cell death.70 Even when mammalian cells are exposed to pre-formed amyloid 
fibrils generated by PolyQ peptides and htt-exon1 exhibited pronounced toxicity. Consistent with 
this, b-sheet rich fibrils of highly aggregate-competent mutant htt-exon1 comprising of a short 
polyQ length are potently toxic in cell culture, and Drosophila models suggest that the underlying 
amyloid structure is key to some toxic mechanism.74  
1.6.3. Oligomer-associated toxicity 
 Spherical oligomers were initially identified as precursor species in fibril formation 
associated with htt-exon1. In the past decades, identification, isolation, and characterization of 
oligomeric species has been of interest. Numerous studies have implied that soluble oligomers, 
rather than mature fibrils, may represent the primary toxic agent in HD. Based on fluorescence 
correlation spectroscopy, oligomers represent early forming aggregate species in cell culture.75 
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Using a combination of microscopic techniques and immunochemical assays, the formation of 
oligomers was confirmed to occur in the brains of the R6/2 and HdhQ150 knock-in mouse model.76 
In addition, oligomers from these mouse models were biochemically and morphologically 
indistinguishable from htt oligomers formed in vitro from purified protein. Further studies with 
the HdhQ150 mouse model revealed an increase in the soluble pool of htt oligomers within the 
first 2 months of life, but this oligomer pool declines with age as the formation of insoluble 
inclusions occurs.77 This may be due to the incorporation of oligomers into inclusions. Using a 
number and brightness method to analyze confocal laser microscopy images, oligomers of GFP-
fused htt-exon1 formed on-pathway to inclusion body formation,78 and inclusions contain a 
heterogeneous mixture of oligomers based on EM experiments and immune-labeling.54 Htt dimers 
and other larger multimers have been isolated from insects and mammalian cells.79  
 Evidence supporting a toxic role of oligomers is multifaceted. Using FCS, the formation 
of htt-exon1 dimers and tetramers was identified as the first marker of the cell pathology.80 Early 
nuclear DNA damage with cell models expressing mutant htt-exon1 occurs concurrently with the 
formation of diffusible aggregates (oligomers), while sedimentable aggregates (fibrils) only appear 
at later time points. Overexpression of profilin, an abundant cellular protein that preferentially 
binds to oligomers, reduces htt toxicity, supporting a toxic role for oligomers.81 Oligomers are also 
linked to ER stress that occurs prior to visible inclusion formation.82–84 
 It may be true that both soluble and insoluble species engender neurotoxicity, albeit 
through different mechanisms. For example, soluble htt oligomers may promote cell death via 
apoptosis induced by mitochondrial dysfunction, whereas, insoluble aggregates cause 
coaggregation of essential cellular machinery, resulting in slower cell death via necrosis.85 This 
hypothesis argues against the notion that a single aggregate species is toxic. More discrepancies in 
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assigning toxicity to a specific molecular state originate from continuous production of htt 
monomers that fuel the aggregation process, multiple intermediate stages, and lack of precision in 
the microscopic techniques to distinguish between these species. Further studies to narrow the 
molecular states during early toxic events are critically important in understanding HD and its 
pathology.  
1.7. The role of Nt17 nucleating aggregation  
 Although htt aggregation is polyQ length dependent, the protein context of the polyQ tract 
strongly influences aggregation and toxicity. Of particular interest is Nt17, which impacts polyQ 
structure, aggregation propensity, and aggregate stability. Several aggregation mechanisms appear 
to be mediated by Nt17. Specifically, Nt17 is implicated in driving the initial stages of htt 
aggregation via oligomerization.86–89 Nt17 is predominantly a disordered random coil in 
solution,90,91 but it undergoes a conformational transitions to adopt an amphipathic α-helical 
structure when exposed to binding partners.64,90,92–94 This propensity to form an amphipathic α-
helix leads to intermolecular association of Nt17 domains to form α-helix rich oligomers that lower 
the energy barrier to nucleation by bringing polyQ tracts into close proximity.60,64,80,90,95,96 
Interestingly, the influence of Nt17 on the aggregation of PolyQ peptide is independent of the 
position, as Nt17 incorporated to either N-terminal and C-terminal sides of PolyQ peptides 
promote the aggregation.64 Similarly, htt-exon1 fragments lacking Nt17 aggregate much more 
slowly than full length htt-exon1.97 These peptide models imply the necessity of the homotypic 
association of Nt17 as a key to multimeric nucleus formation and thereby offering Nt17 as an 
intrinsic enhancer to htt aggregation. 
By probing sporadically populated oligomer species with atomic resolution by NMR, a 
branching pathway for the initial multimerization event of Nt17 has been recently proposed.60 In 
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this model, the hydrophobic interaction between two helices drives the formation of two types of 
antiparallel dimeric subunits, one classified as non-productive (incapable of further 
oligomerization), and the other being productive by assembling into a symmetric tetramer with an 
orthogonal orientation of two dimers. The model provides further support for the amphipathic 
characteristics of helices as hydrophilic residues within tetrameric units are solvent exposed, and 
available to further electrostatic and amphipathic interaction. The tetrameric subunit is compatible 
with the notion that oligomerization localizes PolyQ tracts into close proximity and promoting 
fibril nucleation. Nt17 mostly retains helical structure in fibrils.98 However, this α-helical structure 
does not necessarily propagate along the entire length of Nt17. The C-terminal region may remain 
disordered in the fibril structure, providing flexibility for structural transition to the antiparallel β-
sheet rich fibril core.87,95,99  
 Nt17 may also be directly involved in intermolecular interaction with polyQ that promote 
amyloidogenic conformers.97 That is, interactions between polyQ and Nt17 may stimulate 
conversion within the polyQ region to aggregation-prone conformation. Co-incubation of Nt17 
peptides (no polyQ domain) with pure polyQ peptides (no Nt17) enhances aggregation, supporting 
the notion of a strong intermolecular interaction between Nt17 and polyQ. In similar experiments, 
incubating Nt17 peptide (no polyQ domain) with htt-mimicking peptides containing Nt17 domain 
suppressed aggregation. The free Nt17 peptides are thought to incorporate into htt oligomers that 
are initially formed by intermolecular association of Nt17 domains. The incorporated free Nt17 
peptides effectively act as spacers, increasing the distance between polyQ domains and 
suppressing nucleation.89   
 Given the substantial contribution of Nt17 in htt aggregation, targeting this domain as a htt 
aggregation modulator has been subject to an active investigation. Removing N17 via cleavage11 
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and targeting N17 directly via molecular chaperones97 or antibodies are common strategies.100 
Removal of Nt17 leads to a peptide with a significantly decreased aggregation kinetics.11 The 
chaperonin TRiC, blocking the hydrophobic face of the Nt17 helix, renders a dominant negative 
effect on htt aggregation in vitro and in vivo.97 The Hsc70 chaperon also binds Nt17, competing 
with the homotypic interaction between Nt17 domains that trigger the aggregation process.101 
Moreover, Introducing prolines as helix-breaking (HB) or polyalanine residues to the Nt17 tract 
has been shown to block the aggregation of htt, indicating the specific characteristic of Nt17 in the 
stability of the aggregated htt conformation.97 As a result, Nt17 appears to be a viable therapeutic 
target. Importantly, due to Nt17’s role in initiating oligomer formation that leads to fibrillization, 
targeting it could prevent the formation of both types of htt aggregates.  
1.8. Htt membrane localization is implicated in toxic mechanism   
 A complicating cellular factor in unraveling mutant htt toxicity is the modifying impact of 
association with a great number of membranous surfaces. Htt is significantly associated with 
membranous organelles, including mitochondria, endoplasmic reticulum (ER), the nuclear 
envelope, tubulovesicles, endosomes, lysosome, and synaptic vesicles.47,66,83,102,103 These 
observations indicate a strong htt/lipid binding interaction that may be related to the physiological 
and pathological role of htt.  
 The strong htt-lipid interaction is demonstrated by studies in cellular and mouse model as 
well as HD brain human cells. Membrane compartments are incorporated onto the surfaces of htt 
inclusion bodies in cellular models.4,104,105 Inclusions formed in HD mouse models and 
immortalized human cells directly interact with cellular endomembrane that implicated in cellular 
damage.106,107 The ability of htt to bind membranes are potentially modified by aggregation state, 
and distinct aggregation pathways may be induced on a membrane surface. Supporting the first 
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notion, htt oligomers localize to the postsynaptic membrane involved in membrane trafficking and 
several other neurological features of HD in R6/2 mice.106 Htt associate with the outer 
mitochondrial membrane and mitochondrial structural proteins, leading to mitochondrial 
fragmentation, abnormal mitochondrial dynamics, and oxidative DNA damage.108 While 
oligomers may transiently exist in the bulk solution due to the intermediated nature, subcellular 
localization of oligomers can still promote future aggregation or even stabilize the oligomers that 
lead to cytotoxicity. 
 With the localization of htt to membranes being established, unraveling the mechanistic 
details of htt/lipid interactions are of great interest. It is worth noting that lipid membranes, 
providing a 2-dimensional scaffold, are a common modulator of amyloid formation.109 Several 
physiological properties of the lipid membrane, such as fluidity, curvature, elasticity, modulus, 
surface charge, alter the aggregation of amyloid protein.109,110 PolyQ peptides and htt-exon1 all 
demonstrate altered aggregation in the presence of membranes compared to the bulk solution.88,111–
113 Using a supported lipid membrane model, polyQ length-dependent interaction of htt-exon1 and 
synthetic peptide with lipid membrane was indicated that resulted in altered htt aggregation and 
disruption of the membrane integrity.111 Htt association and aggregation on lipid membranes alter 
the local mechanical properties of the lipid membrane, leading to membrane 
permeabilization.88,112,114,115 As htt interaction and aggregation at lipid surfaces represent a 
fundamental step in several pathogenic mechanisms associated with HD, understanding a detailed 
understanding of the interaction of htt with cellular and subcellular surface is significant. 
Moreover, blocking the ability of htt to directly bind to lipid membranes represents a novel 
therapeutic strategy for HD. There are many reports of membrane permeabilization caused by 
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mutant htt with expanded polyQ;88,114 however, it is not clear whether these effects are specific to 
fibrillar assembly nor whether they are common to other types of spices like oligomers.  
1.9. Nt17 Function as a lipid binding domain 
 As previously mentioned, Nt17 is a random coil in aqueous solution that can adopt an 
amphipathic α-helical conformation which associates with lipid membranes.91,92,116 Nt17 mediates 
trafficking of htt-exon1 to membranes associated with ER, mitochondria, and Goli, contributing 
to mutant htt-induced disruption of cellular calcium homeostasis.92,117 Nt17 is essential for 
insertion of htt into a variety model of lipid bilayers, lending support to the notion that Nt17 plays 
a key role in htt function and toxicity.88,118  
 Based on molecular dynamics, a mechanism for Nt17 lipid binding has been 
proposed.116,119,120 In this mechanism, membrane anchoring is initially driven by electrostatic 
interaction between hydrophilic residues of Nt17 and the lipid headgroups. Next, Nt17 structurally 
reorganizes to position nonpolar residues near the bilayer. Ultimately, nonpolar residue partition 
inside the hydrophobic core of the membrane with a nearly parallel alignment as Nt17 competes 
adoption of its α-helical structure. Furthermore, Nt17 membrane association provides a scaffold 
that promotes intermolecular Nt17 interactions, inducing multimerization on the membrane 
surface. Thereby, Nt17 localization with lipid membrane can produce a high local concentration 
of polyQ domains that may trigger nucleation and facilitate aggregation; however, this appears to 
be dependent on the lipid composition.  
1.10. Importance of lysine residues in Nt17  
 As the importance of Nt17 in htt aggregation has been well established, efforts have been 
put forth to understand the structural details of the role specific residues in Nt17 play in mediating 
aggregation and toxicity. Of particular interest are the three lysine residues within Nt17, as lysine 
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has the ability to participate in both hydrophobic and electrostatic interactions, both of which often 
play prominent roles as mediators in aggregation. In many cases, disrupting interactions associated 
with lysine resides significantly interferes with amyloid formation.121–125 
 The lysine residues within Nt17 reside at positions 6, 9, and 15 (K6, K9, and K15). These 
residues appear to play a vital role stabilizing htt oligomers95 and lipid binding.126 Of the three 
lysine residues, K6 and K15 are located at the edge of the hydrophilic/hydrophobic interface in the 
amphipathic helix, giving them the potential to participate in stabilizing salt-bridges when Nt17 
domains self-assemble into α-helix rich oligomers. K6 and K15 undergo significantly less 
deuterium back-exchange in aggregated forms of huntingtin.127 Deuterium protection of these 
buried residues is indicative of structural protection, supporting contributions of K6 and K15 in 
intermolecular interactions in the aggregated state. Rapid back exchange of K9 suggests that it 
remains accessible, which is consistent with its location in the amphipathic α-helix.127 These 
observations of the relative importance of these different lysine residues in stabilizing oligomers 
is consistent with a more recently reported tetrameric structure of Nt17.60 
 Lysine residues in Nt17 play a critical role in membrane binding as well. NMR-based 
topological analysis of the conformational ensemble of Nt17 residues in micellar environment 
demonstrated the parallel angle of the a-helix axis to the lipid membrane.116 In this orientation, 
K15 is buried in the lipid structure, and K6 and K9 are more exposed to the aqueous phase. This 
arrangement facilitates electrostatic interactions between Nt17 domains and possibly with the 
proximal polyQ tract. High resolution atomistic model of Nt17 obtained by MD simulation in the 
presence of POPC further unveiled essential interactions between lysine residues and 
membranes.128 Based on this model, K6 and K15 are involved in several hydrogen bonds with the 
oxygen of the phosphate groups and several salt-bridges with the negatively charged 
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phospholipids. Such salt bridges with high probability of occurring appear to be the critical 
components of the interaction of Nt17 with the bilayer. While K9 has a lower probability of 
forming salt-bridges with the phospholipids, contrary to the other lysines, it is often associated 
with intramolecular salt-bridges with other amino acids.128,129  
1.11.  Post translational modification of Nt17 alter htt aggregation and lipid binding  
 Another key player in htt subcellular localization, clearance, and aggregation is 
posttranslational modification (PTM) within Nt17. Given the critical role of Nt17 in aggregation 
and membrane association, considerable effort has been devoted to identifying PTMs within Nt17 
and the consequence of these modifications on htt toxicity, cellular function, self-association, and 
lipid binding properties.130–134 Nt17 domain contains various sites that undergo PTMs, including 
Phosphorylation,131, Acetylation,126 Ubiquitination,135 SUMOylation, Oxidation (Fig 1.4).  
 
Fig 1.4 View down the barrel of α-helix conformation of Nt17 showing relative hydrophobicity of each 
residue as well as the sites of reported post-translational modification.  
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There are three phosphorylation sites within Nt17: Threonine 3 (T3), Serine 13 (S13), and serine 
16 (S16). Phosphorylation of Nt17 reduces htt toxicity and initiates a protective response in 
transgenic mice.131,136–140 Introduction of phosphomimic mutation at S13 and S16 in transgenic 
mouse models reduce visible htt inclusions within the brain and were associated with improved 
phenotype.138 In vitro, these same phosphomimetic mutations within htt peptides significantly 
slowed aggregation and reduced structural flexibility and stability of the resulting fibrils.90,141,142 
This is consistent with the introduction of negative charges near the C-terminus of an α-helix 
destabilizing its structure. The helicity disrupting effect of phosphorylation likely reduces the 
efficiency of forming Nt17-mediated oligomers known to be involved in nucleating fibrillization.  
 Lysine residues within Nt17 can undergo acetylation, SUMOylation, and 
ubiquitination.126,132,135 Proteomic mapping by MS demonstrated that K9 is substantially 
acetylated in mammalian cell lysates,143 and this residue is preferentially chemically acetylated in 
vitro.126 Acetylation across all three lysine residues in Nt17 retards fibril formation in solution and 
promotes larger globular aggregates.126 However, selective acetylation at an individual lysine does 
not impact aggregation.144 Nt17 acetylation also reduces the affinity of htt for lipids, limiting its 
ability to cause membrane disruption and ameliorate htt-induced toxicity.126 Ubiquitination of 
Nt17 tags htt for degradation by the ubiquitin proteasome system (UPS), reducing mutant htt 
toxicity in knock-in mouse model of HD.135 Competing with ubiquitination, SUMOylation of Nt17 
also modifies HD pathogenesis.132 SUMOylation at K6 and K9 reduce aggregation by stabilizing 
htt-exon1 fragments in cultured cells, but this is associated with exacerbated toxicity in 
Drosophila.132 The small G protein, Rhes, which serves as a SUMO E3 ligase, preferentially binds 
mutant htt, inducing SUMOylation.145 Overexpressing Rhes in a striatal cell line elicited a 
pronounced increase in soluble mutant htt, exacerbating cytotoxicity. However, mutating Nt17 
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lysine residues to arginine interferes with Rhes-induced htt SUMOylaltion, abolishing 
cytotoxicity.145 Another E3 SUMO ligase, PIAS1, regulates htt SUMOylation in Drosopophila 
models, and reducing expression of PIAS decreased accumulation of insoluble htt with an apparent 
effect.146 Over-expressing PIAS in the R6/2 HD mouse model of HD increases protein deposition 
and exasperates behavioral phenotype.147 
As PTMs regulate cellular events, understanding of the pathophysiological relevance of PTMs in 
htt aggregation would provide details of how mutant htt affects cell function leading to 
neurotoxicity. Besides, identifying regulatory factors of Nt17 PTMs may provide novel therapeutic 
targets. In addition, elucidation of the implication of PTMs in htt aggregation is critical for 
understanding the context-dependent structural impact of Nt17 mediated aggregation mechanisms. 
Broad knowledge of the structure/function relationship of Nt17 can potentially lead to developing 
strategies to manipulate Nt17 function to treat HD. 
1.12. Dissertation outline and study rational  
Although significant strides have been made in understanding HD, no therapeutic has been 
discovered to stop the progression of the disease. Htt aggregation has been long associated with 
HD. Nt17 is strongly believed to impact the aggregation of htt and function as the lipid binding 
domain. Varieties of strategies have been applied to regulate the propensity of Nt17 to self-
associate, and its ability to bind membranes can be regulated. PTMs within Nt17 affect both 
aggregation and membrane binding. Furthermore, a variety of htt aggregates are incorporated into 
cellular lipid membranes in cellular and animal HD model, as well as in postmortem HD brains, 
yet little is known about how aggregated forms of htt actively interact with cellular membranes. 
Based on these critical gaps in our understanding of HD, the following topics are addressed in this 
dissertation:  
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1. The impact of Nt17 SUMOylation on htt aggregation and membrane activity. While 
SUMOylation affects the accumulation of htt inclusions in cells, there is no characteristic 
clarification of the impact of SUMOylation on more diffuse forms of htt aggregates. 
Furthermore, the impact of SUMOylation on htt membrane activity is completely lacking. 
In Chapter 2, the direct impact of SUMOylation of Nt17 on htt aggregation is characterized, 
and SUMOylation promotes the formation of large, SDS-soluble amorphous aggregates of 
htt. Additionally, the influence of SUMOylation on htt membrane activity was 
investigated, and SUMOylation greatly inhibited the ability of htt to bind and aggregate on 
lipid membranes.  
2. The role of aggregation state on htt’s ability to interact with lipid membranes. While the 
association of htt with lipids is well established, there has been no biophysical investigation 
into how aggregation state impacts htt/membrane interactions. Chapter 3 investigates the 
propensity of a distinct htt aggregates to bind lipid membranes. Based on these studies, htt 
oligomers have the highest membrane affinity. In an attempt to specifically characterize 
the binding of htt oligomers to lipid membranes, a crosslinking strategy directed at lysine 
residues within Nt17 was employed to stabilize transient oligomers. While large doses of 
the crosslinking agent indeed stabilized oligomers, low doses surprisingly enhanced 
fibrillization. While the initial strategy was to use stabilized oligomers to understand how 
to interact with lipid membranes, crosslinking actually abolished their membrane activity, 
and this correlated with a reduction in their cytotoxicity, suggesting htt/lipid interactions 
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2. SUMOylation Prevents Huntingtin Fibrillization and Localization onto 
Lipid Membranes1 
2.1.  Abstract  
 Huntington’s disease (HD), a genetic neurodegenerative disease, is caused by an expanded 
polyglutamine (polyQ) domain in the first exon of the huntingtin protein (htt). PolyQ expansion 
destabilizes protein structure, resulting in aggregation into a variety of oligomers, protofibrils, and 
fibrils. Beyond the polyQ domain, adjacent protein sequences influence the aggregation process. 
Specifically, the first 17 N-terminal amino acids (Nt17) directly preceding the polyQ domain 
promote the formation of α-helix-rich oligomers that represent intermediate species associated 
with fibrillization. Due to its propensity to form an amphipathic α-helix, Nt17 also facilitates lipid 
binding. Three lysine residues (K6, K9, and K15) within Nt17 can be SUMOylated, which 
modifies htt’s accumulation and toxicity within cells in a variety of HD models. The impact of 
SUMOylation on htt aggregation and direct interaction with lipid membranes was investigated. 
SUMOylation of htt-exon1 inhibited fibril formation while promoting larger, amorphous 
aggregate species. These amorphous aggregates were SDS soluble but nonetheless exhibited levels 
of β-sheet structure similar to that of htt-exon1 fibrils. In addition, SUMOylation prevented htt 
binding, aggregation, and accumulation on model lipid bilayers comprised of total brain lipid 
extract. Collectively, these observations demonstrate that SUMOylation promotes a distinct htt 
aggregation pathway that may affect htt toxicity.  
 
1 Reprinted with permission from Faezeh Sedighi, Adewale Adegbuyiro, and Justin Legleiter 
ACS. Chem. Neurosci. 2020 11 (3), 328-343 DOI: 10.1021/acschemneuro.9b00509. Copyright 2020 American 
Chemical Society. 
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2.2. Introduction  
Huntington disease (HD) is an autosomal dominant neurodegenerative disorder caused by 
expansion of a polyglutamine (polyQ) stretch beyond a critical threshold in the huntingtin (htt) 
protein.11 Once the critical threshold is reached, there is a strong correlation between polyQ length 
and disease pathology, i.e. age of onset.2,3 In addition, expanded polyQ induces aberrant htt 
aggregation into fibrils similar to amyloids associated with other neurodegenerative diseases.4–7 
The rate of fibril formation also accelerates with increasing polyQ length.4,5,8 Htt aggregation leads 
to the eventual formation of large, proteinaceous inclusion bodies within the cytoplasm and 
nucleus.9 These inclusions can damage ER and nuclear membranes.10,11 Htt aggregation is a 
complex, heterogeneous process with a variety of different aggregate species forming on and off 
pathway to fibril formation. These smaller, intermediate aggregates include a variety of oligomers 
and protofibrils.8,12–18 Cell survival analysis suggests that, rather than inclusions, these nanoscale 
aggregates that are diffusely distributed throughout the cell represent the most toxic species of 
mutant htt.19–22Importantly, this diffuse milieu of htt within cells can contain a mixture of 
oligomers and fibrils,12,23–25 making it difficult to precisely assign toxic mechanisms to specific htt 
aggregate species. 
 While the expanded polyQ domain in the first exon of htt is responsible for aggregation, 
flanking sequences surrounding the polyQ significantly influence the aggregation process. A 
polyproline (polyP) region directly adjacent to the C-terminal side of the polyQ domain stabilizes 
an aggregation incompetent monomeric conformation that retards fibril formation.26,27 Unlike 
polyP, the first 17 amino acids of the N-terminus of htt (Nt17) that directly precedes the polyQ 
domain enhance fibrillization.14,27 In solution Nt17 predominately behaves like an intrinsically 
disordered sequence, but it adopts an amphipathic α-helical conformation upon interaction with a 
binding partner, which underlies its affinity for lipid membranes.28,29 This ability to form an 
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amphipathic αhelix is implicated in the nucleation of htt aggregation as Nt17 domains self-
associate to form α-helix rich oligomers, facilitating fibrillization by bringing polyQ domains into 
close proximity.14,27,30 As oligomers31,32 and fibrils33,34 have been demonstrated to be toxic, Nt17 
mediated oligomerization associated with fibril nucleation may play a crucial role in HD 
pathogenesis.35 Indeed, Nt17 appears to be a viable target for inhibiting htt aggregation.30,36,37 Htt 
is a multifunctional protein,38 and many of these functions are associated with its ability to interact 
directly with a variety of lipid surfaces.39,40 For example, htt localizes to brain membrane 
fractions,41 including the ER,22,42–45 mitochondria,46–51 and plasma membrane.52 Additionally, htt 
participates in the transport of lipid vesicles (endocytic, synaptic, or lysosomal).53–55 The 
interaction of htt-exon1 with lipid membranes is facilitated by Nt17,29,56,57 and htt with expanded 
polyQ domains disrupts a variety of subcellular membranes.58,59 While it is clear that lipids alter 
htt aggregation, literature reports have suggested both enhanced50,60 and inhibited29,36,61–64 htt 
fibrilization in the presence of membranes, depending on the lipid system used.  
 The propensity of Nt17 to bind membranes or self-associate can be regulated by several 
posttranslational modifications (PTMs), including phosphorylation,65–68 acetylation,69 oxidation,70 
ubiquitination,9,71 and SUMOylation.72,73 These PTMs in Nt17 have a pronounced impact on htt 
aggregation and fibril stability. For example, phosphorylation of serine 13 and 16 (S13 and S16) 
reduces pathogenesis and accumulation of htt in transgenic mouse models.68 Phosphomimetic 
mutations at S13 and S16 in a variety of htt systems inhibit fibrillization and aggregate stability.74 
The inhibition of fibrillization by phosphorylation appears related to alterations in the nucleation 
process associated with the formation of the α-helical-rich oligomers facilitated by Nt17.74 In 
addition, phosphorylation at threonine 3 (T3) occurs within cells and tissues relevant to HD, and 
phosphorylation of T3 enhanced htt aggregation in drosophila models of HD with reduced 
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toxicity.65 Three lysine residues (K6, K9, and K15) in Nt17 can undergo acetylation, 
ubiquitination, or SUMOylation. With lysine residues playing a potentially important role in the 
formation of α-helical oligomers,75 PTMs of lysine could readily impact htt aggregation. Of the 
three lysine residues, K9 is the most readily acetylated in Nt17, both in vivo69 and in vitro.36 When 
chemically acetylating lysine residues in htt (resulting in a mixture of K6, K9, and K15 being 
acetylated), fibrillization was inhibited.36 However, the aggregation of synthetic htt peptides was 
unaffected when individual lysine residues were acetylated.76 
 While the above-discussed PTMs alter the local physicochemical properties of discrete 
residues in htt, ubiquitination and SUMOylation of htt results in the covalent attachment of 
relatively large proteins directly to Nt17 via lysine residues.72,77 Ubiquitination is known to mark 
proteins for degradation,9,71,78 alter their cellular location, modify protein activity, and 
promote/inhibit protein interactions.79 The small ubiquitin-like modifier (SUMO) proteins are 
remarkably similar to ubiquitin in structure and share similarities in their enzymatic machinery 
mediating their conjugation to proteins.80 In htt-exon1, K6 and K9 are preferentially SUMOylated; 
although, K15 can be SUMOylated to a lesser extent.72 SUMOylation competes with 
ubiquitination for the same lysine residues in Nt17; however, in terms of toxicity, these two PTMs 
display opposing effects when introduced into Drosophila models of HD.72 While ubiquitination 
tags htt for degradation resulting in reduced toxicity,81,82 SUMOylation impairs Previous studies 
demonstrate that htt SUMOylation impacts aggregation and toxicity in a cellular 
environment;72,73,83,84 however, biophysical details of the impact of SUMO on htt aggregation 
remain unclear. Furthermore, it is plausible that SUMOylation of htt via Nt17 would alter the 
ability of htt to interact with lipid membranes. Here, we investigate the direct impact of 
SUMOylation on the aggregate formation and morphology of a mutant htt-exon1 protein in the 
 35 
presence and absence of lipid membranes. We demonstrate that SUMOylation prevents 
fibrillization and promotes the formation of large amorphous htt aggregates that are SDS soluble. 
In addition, SUMOylation abolishes htt’s ability to bind and disrupt lipid membranes. Collectively, 
our observations shed light on the physicochemical properties of diffuse htt aggregates promoted 
by SUMOylation. 
2.3. Materials and Methods  
2.3.1.  Expression and purification of GST-htt-exon1 fusion protein 
 A glutathione S-transferase (GST)-htt-exon1 fusion protein containing 46 repeats of 
glutamine residues was expressed and purified as previously described.85 In summary, GST-htt-
exon1(46Q) expression was induced in Escherichia coli with 1 mM isopropyle β-d-thiogalactoside 
for 4 h at 30 °C. The cells were lysed with lysosome (0.5 mg/mL), and the fusion protein was 
purified by liquid chromatography (LPLC, BioRad) using a GST affinity column. To determine 
protein purity and verify the relevant fractions, gel electrophoresis was performed. Cleavage of the 
GST moiety by the protease factor Xa releases htt-exon1(46Q), initiating aggregation. Fresh, 
unfrozen GST-htt-exon1(46Q) fusion protein was used for all experiments. To remove potentially 
pre-existing aggregates prior to cleavage of GST, stock solutions of the fusion proteins were 
centrifuged at 20,000g for 30 min at 4 °C. All experiments were carried out in an aggregation 
buffer (50 mM Tris-HCl, 150 mM NaCl, pH 7.5). 
2.3.2. In Vitro htt-exon1 SUMOylation 
SUMO1 modification assay was performed with a SUMOylation kit (Active Motif) with slight 
modifications to the protocol described in the manual. To begin to remove the GST tag but delay 
aggregation, GST-htt-exon1(46Q) fusion proteins were exposed to factor Xa for 1 h on ice. 
Following this treatment, htt-exon1(46Q) was incubated with SUMO1, SUMO activation enzyme 
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E1, SUMO E2 enzyme (Ubc9), and Mg 2+-ATP for 1 h at 37 °C. SUMOylation was carried out in 
a 1.5:4 molar ration of SUMO1 to htt-exon1(46Q). For incubation and CD experiment, 
SUMOylation was carried out with a htt concentration of 4 μM. For ThT, PDA, and in situ AFM 
experiments, the SUMOylation step was performed with 8 μM htt to take into account the required 
further dilutions steps associated with those assays, which were performed at a final concentration 
of 4 μM. Htt-exon1(46Q) used for unmodified controls was treated in the same manner but without 
the addition of SUMO1. 
 SUMOylation of htt was verified via Western blot analysis. Following 
the SUMOylation step, aliquots of SUMOylated htt, unmodified htt, and htt in the presence of 
mutant SUMO! were resuspended in sodium dodecyl sulfate (SDS) dissociation buffer, heated at 
90 °C for 5 min, and loaded into polyacrylamide gels. The volume of aliquots was taken to contain 
2 μg of SUMO1. After SDS-PAGE, proteins were electro-transferred to a nitrocellulose membrane 
(0.45 μm). The membranes were treated with blocking reagent and incubated with an anti-SUMO1 
antibody (Enzo, 1:1000 dilution) overnight at room temperature. Blots were washed 3 times with 
TBST for 10 min before incubation with secondary Goat anti-mouse or anti-Rabbit Alkaline 
phosphatase antibodies (Millipore Sigma, 1:1000 dilution). After 3 washes for 10 min in TBST, 
the blots were developed by NBT/BCIP solution. 
2.3.3.  Thioflavin-T Fluorescence Assay (ThT) 
ThT aggregation assays were conducted in a 384-well plate format using a microplate reader 
(SpectraMax M2). Stock ThT was prepared in ultrapure water at 1.0 mg/mL. The final ThT 
concentration in each well was 0.06 mg/mL. The aggregation of unmodified htt-exon1(46Q) with 
or without free SUMO and SUMOylated htt-exon1(46Q) was determined at a final concentration 
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of 4 μM. The fluorescence intensity was measured using 440 nm excitation and 484 nm emission 
wavelength with 5 min interval for 15 h at 37 °C. All experiments were performed in triplicate. 
2.3.4. Circular Dichroism (CD) Spectroscopy 
To prepare samples for CD measurement, GST-htt-exon1(46Q) fusion proteins were dialyzed 
against Tris buffer (20 mM, pH 7.3) for 24 h at 4 °C before cleavage of GST by factor Xa. Htt-
exon1(46Q) final concentration 4 μM for both unmodified and modified samples. Solutions of 
SUMO1, enzymes, and ATP were prepared to determine the background signal. As the solutions 
provided by the SUMOylation kit caused a large increase in the high-tension voltage, an additional 
dialysis step was required to obtain CD spectra. Background solutions required 24 h of dialysis to 
reduce the high-tension voltage to appropriate levels. As a result, spectra were obtained at 1 h after 
addition of the factor Xa for an unmodified htt-exon1(46Q) sample (which did not require the extra 
dialysis step) and after 24 h of incubation in a mini dialysis kit for unmodified and SUMOylated 
htt-exon1(46Q) samples. Samples were transferred to a 1 mm quartz cell, and CD spectra were 
obtained using a JASCO J-810 spectrometer with 50 nm/min scanning speed and 0.1 nm data pitch 
at 20 °C. Five spectra were collected between 190 to 260 nm for each sample and averaged 
together. Deconvolution of spectra was perfumed using DICHROWEB. 
(http://dichroweb.cryst.bbk.ac.uk/html/home.shtml).86 
2.3.5.  Filter Retardation and Dot Blot Assay 
 Following the SUMOylation procedure, 10 μM solutions containing either unmodified htt-
exon1(46Q) or SUMOylated htt-exon1(46Q) were incubated at 37 °C. As a positive control for 
fibril formation, a 20 μM solution of unmodified htt-exon1(46Q) was also incubated. After 1, 3, 
5, 8, and 12 h of incubation, 2.5 μg of htt was removed from each solution and boiled in 300 μL 
of 0.5% of sodium dodecyl sulfate (SDS) loading buffer for 5 min and stored at room temperature. 
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After prewetting a nitrocellulose membrane (0.45 μm pore size) with TBS for 5 min, a Manifold 
slot blot apparatus (GE Healthcare) was assembled and connected to a vacuum. Each slot was 
washed with 300 μL of TBS and allowed to run through the membrane under vacuum. Each 300 
μL sample was pulled through the membrane in individual slots. The membrane was removed 
from the manifold, soaked in blocking buffer at 4 °C overnight, and incubated with either the htt-
specific monoclonal antibody MW8 (Developmental Studies Hybridoma Bank, University of 
Iowa, 1:350 dilution) or a SUMO1 antibody (Enzo, 1:1000 dilution) at room temperature for 1 h. 
After washing with TBS, the membranes were incubated with secondary Goat anti-mouse or anti-
Rabbit Alkaline phosphatase antibodies at a 1:1000 dilution. Following further washes, the 
membrane was incubated in BCIP/NBT substrate for 15 min to allow color development to verify 
the specificity of the MW8 antibody and the anti-SUMO antibody. Dot blots were also performed 
by spotting 2 μL of incubated (8 h) solutions of SUMO1, htt-exon1(46Q), and SUMOylated htt-
exon1(46Q) directly onto a nitrocellulose membrane. 
2.3.6.  Atomic Force Microscopy (AFM) 
All AFM experiments were performed with a Nanoscope V Multimode atomic force microscope 
(Veeco, Santa Barbara, CA). For ex situ AFM experiments, images were obtained in the tapping 
mode with diving-board-shaped silicon-oxide cantilevers with a nominal spring constant of ∼40 
N/m and resonance frequency of ∼300 kHz (μMasch). Samples were prepared by taking 3 μL 
aliquots of each sample and deposited on freshly cleaved mica, allowed to set for 1 min, then 
washed with 200 μL of ultrapure water, and dried with a gentle stream of air. For in situ AFM 
experiments, a tapping mode fluid cell with an O ring was equipped with a rectangular-shaped 
silicon nitride cantilever (Vista Probes) with a spring constant of 0.1 N/m. Lyophilized TBLE 
(Avanti Polar Lipids, Alabaster, AL) was reconstituted in 25 mM Tris to a concentration of 1 
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mg/mL. Using liquid nitrogen, 10 freeze–thaw cycles were performed to form bilayer sheets. Prior 
to experimentation, the lipid samples were bath sonicated for 10 min to promote lipid vesicle 
formation. TBLE vesicles (30 μL of a 1 mg/mL solution) were injected directly into the fluid cell 
and allowed to fuse into a supported lipid bilayer on mica. The formation of the bilayer was 
monitored by continuous AFM imaging until a 30 μm × 30 μm bilayer free from holes was formed 
(Fig 2.1).  
 
Fig 2.1 Time resolved in situ AFM images of a TBLE bilayer forming  
Once the bilayer formed, 30 μL samples were injected directly into the fluid cell to achieve a final 
htt concentration of 4 μM in the cell. Aggregation on the lipid bilayer was monitored by continuous 
imaging. Images were processed utilizing Matlab equipped with the image processing toolbox 
(MathWorks, Natick, MA) as described.87 Images were flattened to correct for background 
curvature. To automatically identify individual aggregates, AFM images were converted into 
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binary maps based on a height threshold, and clusters of pixels were identified with a recognition 
algorithm. Physical features of individual aggregates (e.g., height, volume, diameter, shape factor, 
length, aspect ratio, length, and area covered) were determined. 
2.3.7. TBLE/PDA Lipid Vesicle Protein Binding Assay 
 TBLE/polydiacetylene (PDA) lipid binding assays were performed as described.88 TBLE 
and 10, 12 tricosadiynoic acid (Fisher Scientific) were mixed in a 2:3 molar ratio in 4 mL of 
ethanol/chloroform (1:1). The solution was dried under a nitrogen stream for 5 min, leaving a thin, 
dry film. Films were reconstituted in 8 mL of 25 mM Tris buffered saline at 70 °C. The solution 
was sonicated for 5 min at 100 W using a sonic dismembrator (Fisher Scientific). The suspension 
was cooled and stored at 4 °C overnight to allow for self-assembly of vesicles. The diacetylene 
monomers were polymerized by irradiation at 254 nm with a UV lamp with stirring to obtain a 
blue PDA/vesicles solution. The vesicles solution was covered with foil and stored in 4 °C prior 
to experiment. 50 μL of 8 μM unmodified htt, SUMOylated htt-exon1(46Q), and unmodified htt 
in the presence of free SUMO were mixed with 50 μL of PDA solution in a 96 well plate format, 
resulting in a final htt concentration of 4 μM. All experimental conditions were performed in 
triplicate on each plate. The % colorimetric response (%CR) of each well was recorded over 5 h 
with 5 min between readings using a microplate reader (SpectraMax M2) at 25 °C based on the 
following equation: %	𝐶𝑅 = '!"!#!"
!"!
( × 100 (1) where PB, defined by Ablue/(Ablue + Ared), was 
calculated for the control (PB0) and each sample condition (PB). Ablue is the absorbance measured 
at 640 nm, and Ared is the absorbance measured at 500 nm. The negative control included equal 
ratios of PDA/lipid solution and buffer, while the positive control included saturated NaOH (pH = 
12) to create a range of colorimetric response for each lipid system. To correct for residual signal 
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associated with free SUMO1, all experiments that included SUMO1 used a corresponding control 
SUMO1 only reaction as PB0. 
2.4.  Results  
2.4.1. Htt-exon1(46Q) is readily SUMOylated in Vitro 
Htt-exon1(46Q) Is Readily SUMOylated in Vitro. Experiments presented in this study were 
performed with a mutant htt fragment that expresses exon 1 with 46 repeats of the polyQ domain 
(htt-exon1(46Q)), which was purified from Escherichia coli as a soluble fusion with glutathione 
Stransferase (GST). Addition of factor Xa protease cleaves the GST moiety and initiates 
aggregation. However, an additional step to SUMOylate htt was required. To achieve 
SUMOylation of htt-exon1(46Q), cleavage of the GST moiety by factor Xa was performed for 1 
h on ice followed by a SUMOylation reaction at 37 °C for 1 h. Due to limitations associated with 
the concentration of SUMO1 stock solutions, optimization of the SUMO reaction, and 
concentrations of htt-exon1(46Q) that would form fibrils in a reasonable time frame, the ratio of 
SUMO1 to htt-exon1(46Q) was 1.5:4. For aggregation experiments, we considered the completion 
of the SUMOylation step to be the 0 h reference. The extent of SUMOylation under these 
conditions was evaluated via Western blot analysis89 with primary antibodies specific for SUMO1 
(Fig 2.2). SUMO with no htt appeared as a single band at 17 kDa when detected with the SUMO 
antibody. A mutant SUMO1 protein, supplied with the SUMOylation kit, that does not bind to 
substrates was used as a control by mixing it with htt under SUMOylating conditions. The mutation 
in the SUMO1 proteins was a point mutation of the C-terminal amino acid from glycine to alanine, 
which disrupts the GG motif of SUMO1 that plays a role in the SUMOylation process. The mutant 
SUMO protein appeared as a single band at 17 kDa, demonstrating that nonspecific binding of 
SUMO to htt did not occur to an appreciable extent. When htt-exon1 was added to SUMO1 and 
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appropriate enyzmes, bands of higher molecular weight were detected by the SUMO antibody, and 
these bands corresponded to bands in the WB correlating with htt-exon1(46Q) detected with MW1. 
Due to ambiguity associated with some of the htt bands, densitometry was performed on the WB 
stained with the SUMO antibody to determine the efficiency of the SUMOylation reaction. By 
comparing the density of bands that correlated with htt to the total SUMO signal, it was determined 
that 69−80% of SUMO1 was successfully conjugated to htt. Taking into account the molar ratio 
of SUMO to htt-exon1(46Q), this indicates that ∼15−20% of htt-exon1(46Q) was SUMOylated. 
 
Fig 2.2 Western blot analysis of the SUMOylation of httexon1(46Q) using an anti-SUMO antibody. Control 
interactions were performed with a mutant SUMO protein that cannot be conjugated to lysine residues. 
2.4.2. SUMOylation inhibits htt-exon1 fibrils formation in Vitro and alters aggregate 
morphology 
 Having established conditions to SUMOylate a fraction of htt-exon1(46Q), the impact of 
SUMOylation on htt aggregation was investigated with a Thioflavin T (ThT) fluorescence assay 
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(Fig 2.3). ThT fluorescence is typically associated with binding β-sheet rich structures and is used 
to track fibril formation of amyloid-forming proteins.90 Three conditions were tested: unmodified 
htt-exon1(46Q), unmodified httexon1(46Q) with free SUMO1 (no enzymes were added to 
covalently bind SUMO1 to htt), and SUMOylated htt-exon1(46Q). As SUMO1 contains β-sheet 
content, an additional control experiment was performed with SUMO1, all of the conjugating 
enzymes, and ATP. These samples did not invoke a ThT signal.  
 
Fig 2.3 ThT analysis of unmodified and SUMOylated httexon1(46Q) aggregation. Aggregation of 
unmodified htt-exon1(46Q), unmodified htt-exon1(46Q) with free SUMO1 (unconjugated to htt), and 
SUMOylated htt-exon1(46Q) was monitored by ThT fluorescence. The concentration of htt-exon1(46Q) 
was 4 μM. Error bars are provided for every 6th data point (0.5 h) and represent the SEM over three 
independent experiments. 
Unmodified htt-exon1(46Q) induced a steady increase in ThT fluorescence for the first 3 h, at 
which point a steady-state fluorescence signal was achieved. Incubations of free SUMO1 with 
unmodified htt-exon1(46Q) exhibited a similar aggregation trend that was not significantly 
different from unmodified htt alone. Upon SUMOylation of htt-exon1(46Q), the ThT signal was 
significantly larger than that associated with unmodified htt-exon1(46Q) and steadily increased 
over the entire time-course of the experiment, never reaching a steady-state value. This analysis 
suggests that SUMOylation enhances fibril formation. However, ThT signal intensity varies based 
on the exact morphology of fibrils,91 and a variety of nonamyloid structures and cavities can also 
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invoke ThT fluorescence.92 As a result, further experiments are needed to verify the extent of 
aggregation associated with SUMOylation. 
 To further characterize the impact of SUMOylation on htt aggregation as a function of 
time, 4 μM solutions of unmodified htt-exon1(46Q), free SUMO1 with unmodified htt-
exon1(46Q), and SUMOylated htt-exon1(46Q) were incubated at 37 °C. Aliquots were taken from 
these incubations 1, 3, 5, and 8 h after the SUMOylation reaction was performed, deposited on 
mica, and imaged via AFM (Fig 2.4A).  
 
Fig 2.4 Ex situ AFM images of unmodified and SUMOylated htt-exon1(46Q). (A) Representative AFM 
images of unmodified and SUMOylated htt sampled after 1, 3, 5, and 8 h of incubation. Examples of 
oligomers (blue arrows), fibrils (black arrows), and amorphous aggregates (green arrows) are indicated. 
These examples are based on the criteria described in the text. (B) Correlation plots of average diameter 
vs height of all observed aggregate species. Shaded gray boxes indicating a population of aggregates of 
SUMOylated htt-exon1(46Q) that have a unique combination of morphological features compared to 
unmodified htt-exon1(46Q) controls. 
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For incubations of unmodified htt-exon1(46Q), small oligomeric aggregates were detected after 1 
h. After 3 h of incubation, a small population of short (<500 nm in length) fibrils were present in 
addition to numerous oligomers. The number and size of fibrils appeared to increase with time (5 
and 8 h time points). Similar aggregation patterns and aggregate morphologies were observed for 
incubations of free SUMO1 with unmodified htt (Fig 2.5), and these observations are consistent 
with these two conditions invoking similar ThT responses. When htt-exon1(46Q) was 
SUMOylated, a large population of oligomers was observed after 1 h of incubation; however, 
fibrils did not abundantly form with time. Rather, SUMOylation of htt-exon1(46Q) promoted the 
formation of large, amorphous aggregates that steadily became larger with longer incubation. This 
observation is not consistent with the ThT assay if they are interpreted traditionally, i.e. that 
increased ThT signal is associated with fibril formation. Rather, this suggests SUMOylation may 
promote truncated β-sheet-rich oligomers that conglomerate into large, amorphous aggregation. 
 To evaluate and quantify the different aggregate species associated with unmodified and 
SUMOylated htt, morphological features of all the individual aggregates observed in the AFM 
images were measured with automated algorithms. To visualize the distribution of aggregate 
morphological features, correlation plots of aggregate height vs average diameter (average 
between the width and length of the bounding box associated with each aggregate) were 
constructed (Fig 2.4B). Based on these plots, there is a clear difference in aggregation patterns 
associated with htt-exon1(46Q) and SUMOylated htt-exon1(46Q). A distinct population of htt 
aggregates with heights greater than 15 nm formed from SUMOylated htt. The height of 
unmodified htt-exon1(46Q) aggregates does not appear to continue to increase; rather, the average 
diameter increases as elongated fibrils appear. In contrast, both the height and diameter of 
aggregates of SUMOylated htt continues to grow as amorphous aggregates grow larger in multiple 
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directions. In contrast, comparison of correlation plots of unmodified htt-exon1(46Q) incubated 
with and without free SUMO1 demonstrates that these conditions result in aggregates of similar 
morphological characteristics (Fig 2.5B) 
 
Fig 2.5 Ex situ AFM images of unmodified htt-exon1(46Q) incubated with free SUMO1. (A) Representative 
AFM images of unmodified htt-exon1(46Q) incubated with free SUMO1, that is the SUMOylation enzymes 
were not added, resulting in no measurable SUMOylation of htt-exon1(46Q). The incubation was sampled 
after 1, 3, 5, and 8 h and can be compared to the AFM aggregation assay provide in Fig 2.4 Examples of 
oligomers (blue arrows) and fibrils (black arrows) are indicated. (B) Correlation plots of average diameter 
vs height of all observed aggregate species compared to the unmodified htt-exon1(46Q) control. 
To quantify different aggregate species, present in AFM images for each incubation as a 
function of time, the number of oligomers, fibrils, and amorphous aggregates per μm2 was 
determined (Fig 2.6 and 2.7) by sorting each individual aggregate based on morphological features. 
In the past, we have been successful in sorting htt oligomers from fibrils by using an aspect ratio 
(longest distance across to shortest distance across) filter;87 however, this would not be sufficient 
to distinguish the amorphous aggregates from fibrils and/or oligomers. As a result, extra criteria 
and visual inspection was required. For any set of criteria, our algorithms place labels onto the 
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AFM image to verify the ability to distinguish different aggregate species and allow for manual 
determination for the few aggregates with ambiguous assignments. For this analysis, oligomers 
were defined as any feature taller than 0.8 nm in height with an aspect ratio less than 2.5 (indicating 
a globular structure) and occupying less than 0.01 μm2 of the surface. Amorphous aggregates were 
defined as being at least 0.8 nm in height and occupying a surface area greater that 0.01 μm2. 
Fibrils were defined as aggregates taller than 0.8 nm in height with an aspect ratio greater than 2.5. 
As some aggregate species could meet the criteria for both amorphous aggregates and fibrils, 
differentiating between these ambiguous assignments required visual inspection of the labeled 
aggregate in each AFM image. 
 
Fig 2.6 Analysis of oligomers observed in ex situ AFM images of unmodified and SUMOylated htt-
exon1(46Q). (A) Number of oligomers (based on criteria provided in the text) per unit area observed as a 
function of time. Error bars represent the standard deviation. (B) Comparison of height histograms of all 
oligomers formed from unmodified and SUMOylated htt-exon1(46Q) as a function of time. Due to 
differences in the number of oligomers observed at different time points and conditions, each column is 
normalized by dividing the entire distribution by the number of oligomers contained in the most populated 
bin. 
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 After 1 h of incubation, a similar number of oligomers was observed for both htt-
exon1(46Q) and SUMOylated htt-exon1(46Q) (Fig 2.6A), While the number of oligomers per unit 
area comprised of htt-exon1(46Q) gradually increased with time, SUMOylation of htt-exon1(46Q) 
resulted in a steady decrease in the oligomer population. Presumably, this decrease could be 
attributed to the formation of the large amorphous aggregates sequestering away smaller 
oligomers. Based on height histograms of all oligomers observed (Fig 2.6B), the initial (1 h time 
point) sizes of the oligomers comprised of unmodified htt-exon1(46Q) or SUMOylated htt-
exon1(46Q) were similar (mode height of ∼2–3 nm); however, there was a noticeable population 
of oligomers of SUMOylated exon1(46Q) larger than 7.5 nm (15.9% of the total observed 
oligomers) that was absent in the control htt incubations. With time, the size of unmodified htt-
exon1(46Q) oligomers increased (mode height of ∼3–4 nm), and some oligomers taller than 7.5 
nm were observed (4.1%, 6.0%, and 5.1% of all observed oligomers for time points 3, 5, and 8 h, 
respectively).  
 
Fig 2.7 Analysis of fibrils and amorphous aggregates observed in ex situ AFM images of unmodified and 
SUMOylated htt-exon1(46Q). (A) Number of fibrils (based on criteria provided in the text) per unit area 
observed as a function of time. (B) Number of amorphous aggregates (based on criteria provided in the 
text) per unit area observed as a function of time. Error bars in both (A) and (B) represent the standard 
deviation. (C) Comparison of height histograms of all fibrils and amorphous aggregates observed over the 
entire time frame of the AFM experiment formed from unmodified (−) and SUMOylated (+) htt-
exon1(46Q). Due to differences in the number of fibrils and amorphous. 
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For SUMOylated htt-exon1(46Q), the size of the oligomers increased to a greater extent, reaching 
a mode height of ∼5–7 nm by 8 h of incubation. There was also a prominent population of 
oligomers larger than 7.5 nm at these later time points for SUMOylated htt-exon1(46Q) (15.7%, 
15.6%, 14.7% of all oligomers for time points 3, 5, and 8 h, respectively). 
 While unmodified htt-exon1(46Q) aggregated into fibrils, SUMOylation of htt-
exon1(46Q) promoted larger amorphous aggregates (Fig 2.7). For unmodified htt-exon1(46Q), a 
small number of fibrils formed after 3 h of incubation, and this fibril population grew with time 
(Fig 2.6A). With SUMOylation, fibrils were not observed until after 5 h of incubation, and even 
then the population of fibrils was significantly smaller compared to incubations of unmodified htt. 
In contrast, a significant population of large amorphous aggregates formed in incubations of 
SUMOylated htt-exon1(46Q) as early as 1 h (Fig 2.7B). The raw number of amorphous aggregates 
peaked after 3 h for SUMOylated htt due to these aggregates coalescing into larger aggregates at 
5 and 8 h. Aggregates that fit the morphological criteria for amorphous aggregates were observed 
for incubations of unmodified htt-exon1(46Q), but the population and size of these aggregates was 
significantly smaller compared with SUMOylated htt. As both large fibrils and amorphous 
aggregates occupied larger surface areas, height histograms of all aggregates observed that 
occupied at least 0.01 μm2 were compared for incubations of htt-exon1(46Q) and SUMOylated 
htt-exon1(46Q) (Fig 2.7C). As fibrils grow by addition of htt to their ends, the height of fibrils 
does not increase as they become longer, resulting in a tight distribution of height of ∼5.5–7.5 nm. 
Such a distribution is observed for unmodified htt-exon1(46Q). In comparison, the amorphous 
aggregates grow in all directions, resulting in a broad, nonuniform distribution of height, as seen 
for SUMOylated htt-exon1(46Q). The contrast between the fibril and amorphous aggregate 
morphologies is further illustrated in (Fig 2.8), which compares AFM images and height profiles 
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of the large aggregates observed for both conditions. Fibrils formed by htt-exon1(46Q) are 
typically less than 10 nm in their profiles; however, when fibrils cross or bundle, the height at that 
point can be slightly larger than 10 nm. Amorphous aggregates are more variable in their height 
and can have regions with heights exceeding 20 nm. However, these amorphous aggregates can 
be on the order of hundreds of nanometers in their lateral dimensions. Collectively, this analysis 
indicates that SUMOylation of htt promotes a broad size range of amorphous aggregates while it 
significantly interferes with the formation of fibrils which are typically observed for htt 
aggregation. 
 
Fig 2.8 Representative AFM images demonstrating the different morphologies of (A) fibrils formed by 
unmodified htt-exon1(46Q) and (B) amorphous aggregates of SUMOylated htt-exon1(46Q). The green line 
in each AFM image corresponds to the height profile directly below it. The scale bars in (A) and (B) for 
height profiles are identical. 
2.4.3. Secondary Structure of Aggregated htt Is Altered by SUMOylation 
Despite invoking a strong ThT signal, classic fibril morphology was not observed via AFM. We 
performed CD spectroscopy to glean information concerning the secondary structure associated 
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with aggregation of unmodified and SUMOylated htt (Fig 2.9). Due to interference associated with 
the buffers used for SUMOylation, an additional 24 h dialysis step was required to obtain usable 
CD spectra. As a result, we were restricted to evaluating secondary structure after 24 h of 
incubation after SUMOylation. For unmodified htt-exon1(46Q) we were able to obtain CD spectra 
1 h after the addition of factor Xa prior to performing the SUMO reaction. 
 Based on the CD spectra, unmodified htt-exon1(46Q) underwent a clear structural 
transition between 1 and 24 h of incubation (Fig 2.9A). Comparison of the CD spectra for 
unmodified and SUMOylated htt-exon1(46Q) after 24 h of incubation was clearly distinct. 
Deconvolution of the CD spectra (Fig 2.9B) suggests that htt-exon1(46Q) was comprised 
approximately of an equal mixture of α-helical and coil structure. After 24 h of incubation, 
unmodified htt-exon1(46Q) was predominately comprised of coil (61%) with the helical content 
dropping to 2% of the secondary structure. Consistent with fibril β-sheet content increased to 
account for 37% of the secondary structure. In contrast to unmodified htt, SUMOylated htt retained 
a larger portion of its helical content (13%). While coil still represented the largest secondary 
structural element (45%), a large portion of β-sheet was also present (42%). This suggests that the 
large amorphous aggregates contain significant β-sheet content. 
 While measured β-sheet content by CD spectroscopy was larger for aggregates of 
SUMOylated htt-exon1(46Q), it was not large enough to explain the large increase in ThT 
fluorescence compared with unmodified htt. This apparent discrepancy is plausibly due to a variety 
of factors. The amorphous aggregates indeed contain a significant amount of β-sheet structure to 
which ThT can bind. As the morphologies of aggregates are different for unmodified and 
SUMOylated htt, there could be variation in ThT affinity for these different aggregate types. Such 
a scenario is known for polymorphic fibrils of other amyloid forming proteins.93 ThT fluorescence 
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can also arise from the binding of nonamyloid structures and cavities,92 which may be provided by 
the large amorphous aggregates associated with SUMOylation. Nevertheless, both ThT and CD 
analysis point to a large extent of β-sheet content in aggregates formed by SUMOylated htt despite 
the lack of traditional fibril morphologies. 
 
Fig 2.9 CD spectral analysis of secondary structural elements of aggregates of unmodified and 
SUMOylated htt-exon1(46Q). (A) CD spectra were taken of 4 μM unmodified htt-exon1(46Q) after 1 and 
24 h of incubation and 4 μM SUMOylated htt-exon1(46Q) after 24 h of incubation. The 24 h time-point was 
required to allow for the removal, via dialysis, of elements associated with the SUMOylation buffers that 
interfered with the collection of the CD spectra. As a result, CD spectra at intermediate time-points could 
not be collected. (B) Deconvolution of CD spectra was perfumed using DICHROWEB 
(http://dichroweb.cryst.bbk.ac.uk/html/home.shtml) to determine the content of α-helical, β-strand, and 
coil secondary structural elements. 
2.4.4. SUMOylation Promotes the Formation of SDS Soluble Aggregates 
 To further characterize how SUMOylation of Nt17 altered htt aggregation, unmodified and 
SUMOylated htt-exon1(46Q) was incubated (10 μM), and aggregation was evaluated with a filter 
trap assay, which allows for the detection of SDS insoluble htt aggregates (predominately fibrils) 
that are too large to pass through a nitrocellulose membrane (pore size of ∼0.45 μm) under 
vacuum. In addition, a control incubation of 20 μM htt-exon1(46Q) was also tested as a positive 
control for fibrillization. Captured fibrils were detected with the monoclonal htt antibody, MW8, 
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which is known to recognize htt-exon1 fibrils.94 The incubations (37 °C) of unmodified and 
SUMOylated htt-exon1(46Q) were sampled (2.5 μg) after 1, 3, 5, 8, and 12 h. For control 
incubations of htt-exon1(46Q) that had not been SUMOylated, SDS insoluble aggregates were 
detected after 5 and 8 h for 20 and 10 μM solutions, respectively (Fig 2.11A). Based on the AFM 
analysis, these likely represent fibril aggregates. Once observed, the intensity of the MW8 staining 
increased over time, indicating an accumulation of fibrillar material on the membrane that is bigger 
than the pore size. 
 
 
Fig 2.10 Immunochemical analysis aggregates formed by unmodified and SUMOylated htt-exon1(46Q). A 
filter retardation assay was performed on 10 μM incubations of unmodified and SUMOylated htt-
exon1(46Q) aggregation reactions as a function of time. As a positive control for aggregation, incubations 
of 20 μM htt-exon1(46Q) were also analyzed. Membranes were probed for trapped (A) htt-exon1(46Q) by 
MW8 and (B) SUMO1 by SUMO specific antibody. (C) As a control to verify that MW8 and the anit-SUMO1 
antibody could detect htt-exon1(46Q) and SUMO1, a dot blot was performed on SUMO1, unmodified htt-
exon1(46Q) (20 μM and 10 μM), and SUMOylated htt-exon1(46Q) (10 μM) after 8 h of incubation. 
 
 When htt-exon1(46Q) was SUMOylated, the immunoreactivity with MW8 was absent at 
each time point (Fig 2.11A). Due to the observation of a significant population of large (>500 nm 
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in diameter), amorphous aggregates via AFM, it is reasonable to hypothesize that these htt species 
would be trapped by the filter. However, there are two possible explanations for this observation: 
(1) that MW8 does not recognize the htt contained in these amorphous aggregates or (2) that these 
amorphous aggregates are dissolved by boiling in SDS. To distinguish between these two 
possibilities, the membrane was probed by a SUMO specific antibody provided by 
the SUMOylation kit (Fig 2.11B) because SUMO is likely incorporated into these large 
aggregates. No signal was detected for SUMOylated htt supporting the notion that these large, 
amorphous aggregates are dissolved by boiling in SDS. 
 To verify that MW8 and the anti-SUMO antibody could bind to the large amorphous 
aggregates and eliminate the possibility of a false negative result in the slot blot assay, a dot blot 
assay was performed (Fig 2.10C). Four different conditions were tested: SUMO1 alone, 
unmodified htt-exon1(46Q) (10 and 20 μM), and SUMOylated htt-exon1(46Q) (10 μM). Samples 
were incubated for 8 h to allow for the formation of higher order aggregates before direct 
deposition on a nitrocellulose membrane and probed by MW8 and the anti-SUMO antibody. On 
the dot blot, MW8 detected unmodified and SUMOylated htt-exon1(46Q) samples, but not 
SUMO1 alone. The anti-SUMO antibody detected SUMO1 alone and SUMOylated htt but did not 
detect unmodified htt samples. This suggests that if the large amorphous aggregates of 
SUMOylated htt-exon1(46Q) were retained by the filter trap that they would have been detected 
by both MW8 and the anti-SUMO antibodies. 
2.4.5. SUMOylation Inhibits htt–Lipid Interaction 
 Nt17 functions as a lipid binding domain.35,87 In an effort to understand how SUMOylation 
influences the interaction of htt-exon1 with lipid membranes via Nt17, we performed total brain 
lipid extract (TBLE)/polydiacetylene (PDA) vesicle lipid binding assays. This is a colorimetric 
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assay that can temporally quantify peptide–membrane interactions and interfacial membrane 
processes. The mixed vesicles comprised of phospholipids (in this case TBLE) and polymerized 
PDA exhibit a visible color change (blue to red) induced by interactions between peptides and the 
phospholipid moieties within the vesicles due to transitions of the PDA polymer backbone 
structure.88,95 By measuring absorbance of both the blue (640 nm) and red (500 nm) wavelengths 
associated with the TBLE/PDA vesicles upon exposure to unmodified htt-exon1(46Q) with or 
without free SUMO1 or SUMOylated htt-exon1(46Q) (all at concentrations of 4 μM), the %CR 
was obtained as a function of time (Fig 2.11A). Importantly, the calculation of the %CR can be set 
up to take into account background experiments performed with SUMO1 in the absence of htt. To 
ensure that the htt-exon1(46Q) interacted with the TBLE/PDA vesicles, additional reactions were 
performed with unmodified htt at 20 μM. NaOH exposure served as a positive control to verify 
that the TBLE/PDA vesicles were functioning properly. The TBLE/PDA vesicles were also 
exposed to Tris buffer as a negative control. 
 Upon exposure to htt-exon1(46Q), the %CR increases rapidly for ∼2–3 h until a steady-
state interaction is achieved. As expected, the steady state %CR was 3× larger for htt-exon1(46Q) 
at 20 μM compared to htt at 4 μM (Fig 2.11A). At the 4 μM concentration, the steady-state response 
was ∼7–8%, indicative of the interaction of htt-exon1(46Q) at 4 μM with the lipid vesicles. 
Incubations of free SUMO1 with unmodified htt-exon1(46Q) result in a similar interaction the 
PDA/TBLE vesicle and were not notably different from unmodified htt alone. In contrast, 
SUMOylated htt (4 μM) did not induce a rapid increase in the colorimetric response; rather, the 
%CR was steady at about 2% over 5 h, suggesting that the SUMOylation completely inhibits the 
ability of htt-exon1 to bind and aggregate on lipids. 
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 As the PDA assay suggested that SUMOylation abolished the interaction of htt-exon1 with 
TBLE vesicles, we next performed a series of in situ AFM experiments to further validate this 
observation. Supported TBLE bilayers on mica were prepared via vesicle fusion. Such supported 
bilayers have been previously used as model surfaces to study the interaction of several amyloid-
forming proteins with lipid membranes.96–99 From trial to trial, the total concentration of lipid in 
the AFM fluid cell was maintained, but observations were restrained to a 30 × 30 μm patch of 
bilayer that was verified to be defect-free (at the level of resolution of the AFM) prior to exposure 
to any further proteins. Such TBLE bilayers are smooth with an (RMS roughness about 0.4 nm, 
Fig 2.11B) and stable under AFM imaging conditions (for at least 24 h). To control for any 
influence of the SUMO protein alone on the integrity of the bilayer, control experiments were 
performed by exposing freshly formed TBLE bilayers to the SUMO protein, SUMO enzymes, and 
ATP solution at the same concentrations as would be used in experiments with htt. Following the 
injection of this SUMO solution into an AFM fluid cell, the bilayer morphology was unaffected 
for well over 5 h with no discernible effect on the bilayer roughness (Fig 2.11C). 
 Having established that SUMO alone did not alter TBLE bilayer morphology, TBLE 
bilayers were exposed to either unmodified htt-exon1(46Q) or SUMOylated htt-exon1(46Q) at a 
final concentration of 4 μM in the fluid cell. The protein aggregation on the bilayer was directly 
monitored by continuous in situ AFM imaging for 5 h (Fig 2.11D).  
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Fig 2.11 SUMOylation of htt-exon1(46Q) inhibits the ability of htt to interact with total brain lipid extract 
bilayers. (A) PDA/TBLE lipid vesicle binding assay of 4 μM unmodified htt-exon1(46Q), free SUMO1 with 
unmodified htt-exon1(46Q), and SUMOylated htt-exon1(46Q). Positive control experiments included 
exposure of PDA/TBLE vesicles to 20 μM htt-exon1(46Q). (B) Freshly made TBLE bilayer observed by in 
situ AFM. The green line corresponds to the height profile provided to the right. (C) In situ AFM image of 
a TBLE bilayer exposed to SUMO1 for 5 h. The green line corresponds to the height profile provided to the 
right. (D) Time-resolved AFM images of TBLE bilayers exposed to unmodified htt-exon1(46Q) and 
SUMOylated htt-exon1(46Q). Arrows are provided to demonstrate common features in consecutive images, 
verifying that this is the same spot of the lipid bilayer. The green lines in the 5 h time point correspond to 
the height profile provided to the right. 
Upon initial exposure of the TBLE bilayer to htt exon1(46Q), discrete patches of disrupted bilayer 
morphology (increased roughness) appeared that often contained features reminiscent of htt 
oligomers. Unlike the ex situ AFM experiment performed at the same htt concentration, fibrils 
were not observed on the lipid bilayer; however, the aggregates were globular in appearance and 
remained stable in consecutive images. With time, the area of the bilayer disrupted by exposure to 
htt increased, and the roughness associated with these regions appeared more pronounced. After 5 
h of exposure to htt-exon1(46Q), 44 ± 6% of the TBLE bilayer surface appeared to be disrupted. 
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In contrast, TBLE bilayers that were exposed to SUMOylated htt-exon1(46Q) did not develop 
disrupted regions over the entire 5 h experiment. A few discrete oligomers did appear on the bilayer 
surface, but no large amorphous aggregates were observed, suggesting that SUMOylated htt and 
the resulting aggregates do not readily interact with TBLE bilayers. This observation is consistent 
with the PDA results implying the inhibitory function of SUMO conjugation on htt lipid binding. 
 To quantify the extent of disruption correlated with the interaction of lipid exposure with 
unmodified or SUMOylated htt, the RMS roughness of the different bilayers was measured (Fig 
2.12). For the bilayers exposed to unmodified htt-exon1(46Q), two RMS roughness measurements 
were obtained: one of the patches exhibiting increased roughness (rough) and the other of the 
unaffected regions of the bilayer (smooth).  
 
Fig 2.12 Analysis of the RMS roughness of in situ AFM images of TBLE bilayers exposed to unmodified or 
SUMOylated htt-exon1(46Q). TBLE alone refers to the RMS roughness of lipid bilayers prior to exposure 
to any protein. + SUMO indicates the RMS roughness measured from bilayers exposed to SUMO1 for 5 h. 
+ htt (smooth) refers to the RMS roughness of regions of bilayers exposed to unmodified htt-exon1(46Q) 
that did not display altered morphology. + htt (rough) refers to the RMS roughness of regions of bilayers 
disrupted by unmodified htt-exon1(46Q). + htt (SUMOylation) refers to the RMS roughness of bilayers 
exposed to SUMOylated htt-exon1(46Q). * indicates p < 0.05, ** indicates p < 0.01, and *** indicates p < 
0.001 based on a t test (n = 3). Error bars represent standard deviations. 
Control TBLE bilayers had an RMS roughness of 0.36 ± 0.04 nm, and TBLE bilayers that were 
only exposed to SUMO had an RMS roughness of 0.29 ± 0.05 nm. The smooth regions of bilayers 
exposed to htt-exon1(46Q) were comparable (<0.5 nm) at all time points, but the disrupted regions 
were significantly rougher (>1.0 nm) at all time points, and the roughness increased with time. The 
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RMS roughness of bilayers exposed to SUMOylated htt was comparable to the controls over the 
entire time frame of the experiments, reaching a maximum RMS roughness of 0.41 ± 0.7 nm after 
5 h. 
2.5.  Discussion 
 While the expansion of polyQ domains in proteins is the root cause of numerous diseases,18 
the context of the polyQ domain within the proteins can profoundly influence the disease-related 
aggregation process. In the case of htt, the Nt17 and the polyP sequences directly adjacent to the 
polyQ domain impact aggregation,27,100,101 and both have been shown to be viable targets to inhibit 
htt fibrilization.30,94 Several PTMs (phosphorylation, acetylation, and oxidation) of the Nt17 
sequence impact htt aggregation in vitro.35 In addition, SUMOylation of htt via the Nt17 domain 
has been shown to reduce insoluble htt aggregates in cellular models of HD.72,73,83,84 In this study, 
we investigated the impact of SUMOylation of a mutant htt-exon1 protein on its ability to 
aggregate and interact with lipid membranes. 
 While htt-exon1(46Q) readily aggregated into fibrils, SUMOylation promoted a distinct 
aggregation pathway that resulted in large, amorphous aggregates (Fig 2.13A). Both unmodified 
and SUMOylated htt formed oligomers, but based on morphological analysis, the oligomer species 
appear to be unique. Taking into account the ThT, AFM, and CD data, a mechanism for the SDS 
solubility of the amorphous aggregates formed by SUMOylated htt can be proposed. While only a 
small portion (15–20%) of htt was successfully SUMOylated under our experimental conditions, 
it had a significant impact on aggregation. Unmodified htt-exon1 aggregates via an Nt17 mediated 
α-helix rich oligomer involved in nucleating fibril formation.14,101 A potential scenario 
for SUMOylation’s impact on aggregation could be similar to the mechanism associated with the 
ability of free Nt17 peptides (Nt17 peptides without an adjacent polyQ domain) to inhibit fibril 
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formation.30 Free Nt17 peptides are incorporated into the α-helical intermediates, decreasing the 
density of polyQ within the oligomer, reducing the efficiency of nucleation within the oligomer.30 
SUMO1, being much larger than a free Nt17 peptide, could also create spacing between polyQ 
domains of htt, reducing fibril formation. However, the addition of Nt17 to htt-exon1(46Q) does 
not promote large amorphous aggregates; rather, it appears to stabilize a tight distribution of 
oligomers.37 While the Nt17 peptide is about 2.0 kDa, SUMO1 is an 11.5 kDa protein. Yet, the 
formation of β-sheet structure by SUMOylation under our conditions suggests that nucleation was 
not inhibited. This could be due to only 15–20% of htt being SUMOylated, as inhibition of htt 
aggregation of Nt17 was also dose dependent. As SUMOylated htt that is incorporated into 
oligomers would still contain β-sheet competent polyQ domains, it is also plausible that oligomers 
formed under our SUMOylated condition still facilitate intermolecular polyQ interactions resulting 
in β-sheet structure; however, the bulky SUMO1 proteins prevent, via steric hindrance, further 
addition of htt monomers required for fibril elongation. This would, in effect, create truncated β-
sheet-rich oligomers. These stunted htt oligomers containing SUMO1 conglomerate into large 
amorphous aggregates; however, the presence of SUMO1 prevents the creation of the large-scale 
order that would be associated with standard fibril structures. As a result, the stability of these 
mixed amorphous aggregates would be compromised by the incorporation of SUMO1, making 
them susceptible to be broken apart into fibril-forming incompetent oligomers upon boiling in 
SDS. This scenario is consistent with the height of htt oligomers under SUMOylating conditions 
being similar to the height of htt fibrils, the enhanced ThT fluorescence associated with 
SUMOylated htt, and the development of β-sheet structure with SUMOylated htt as detected by 
CD. 
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 In addition, SUMOylation abolished the ability of htt-exon1 to associate with and disrupt 
TBLE bilayers (Fig 2.13B). As Nt17 facilitates the binding of htt-exon1 to lipid membrane, 
SUMOylation would provide steric hindrance to the binding interaction, but only a fraction of htt 
was effectively SUMOylated. In principle, the unmodified portion of htt-exon1 should have been 
available to interact with lipids unimpeded; however, SUMOylating 15–20% of htt completely 
blocked lipid binding.  
 
Fig 2.13 Cartoon summarizing the impact of SUMOylation on (A) htt-exon1 aggregation and (B) htt-
exon1’s ability to bind lipid membranes. (A) Htt-exon1 with expanded polyQ domains samples a variety of 
monomeric conformations, some of which are aggregation prone. Aggregation of unmodified htt-exon1 
proceeds through an α-helical oligomeric intermediate that is mediated by the Nt17 domain on the way to 
forming amyloid fibrils. When a subpopulation of htt-exon1 is SUMOylated via Nt17, a distinct (compared 
to the unmodified condition) oligomer species forms likely due to the incorporation of the bulky SUMO 
constituent in comparison to the size of the Nt17 domain. These intermediates are likely β-sheet rich 
oligomers that are stabilized by steric hindrance associated with the incorporation of SUMO1. These 
oligomers tend to grow in size rather than transitioning to a fibrillar morphology, eventually coalescing 
into large amorphous aggregates that are SDS soluble. (B) Due to its ability to form an amphipathic α-
helix, Nt17 facilitates the binding of htt-exon1 to lipid membranes. Upon the addition of a bulky SUMO 
constituent, the ability of Nt17 to associate with lipid membranes is blocked. 
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A potential mechanism for this is that htt oligomers have formed within the time required to 
perform the SUMOylation reaction. As a result, the control experiment using unmodified htt-
exon1 is measuring the affinity of oligomers for lipid membranes rather than monomers. While 
oligomers of unmodified htt interact strongly with membranes, the inclusion of SUMO1 into htt 
oligomers prevents their ability to bind lipids. Collectively, these observations suggest 
that SUMOylation attenuates the aggregation process of htt and the ability of htt to interact with 
other physiologically relevant molecules and underscores the complexity of htt aggregation. 
 SUMOylation of amyloid-forming proteins is a common phenomenon;102–104 however, the 
impact of SUMOylation on the aggregation of these different proteins varies. For example, α-
synuclein (α-syn) from the brains of transgenic mice is SUMOylated,105 and SUMOylated α-syn 
is found in Lewy bodies in brains from patients with Parkinson’s disease and dementia with Lewy 
bodies.106 Similar to the observed inhibition of htt fibrillization observed here, ∼50% 
of SUMOylation in α-syn abolishes fibril formation, and only 10% SUMOylation can significantly 
delay fibril formation.105 SUMO1 promotes SOD1 aggregation and colocalize into aggregates,107 
and SUMO3 accelerates the aggregation of familial ALS-linked mutant SOD1 proteins. Enhanced 
SUMOylation is a common aspect of polyQ diseases.108 SUMOylation of Ataxin-7, another 
aggregating protein associated with expanded polyQ, stimulated the formation of insoluble 
aggregates;109,110 however, SUMOylation of Ataxin-3 stabilizes the protein, reducing 
aggregation.110,111 SUMOylation also plays a role in the processing of amyloid-forming proteins 
with various impacts on the disease state. APP processing linked to Aβ production is modified by 
SUMOylation.112 SUMO also appear to modify Tau phosphorylation.113  
 While SUMO1 colocalized with htt inclusions, overall inclusions are reduced 
with SUMOylation of htt, htt stability was increased, and overall aggregation was reduced in 
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cellular models of HD.72 While SUMOylation suppressed htt amyloid formation, it promoted htt-
induced neurodegeneration in a drosophila model of HD.72 Rhes, a small G protein family, 
specifically stimulates mutant htt SUMOylation but not wild-type.73 When mutant htt is 
SUMOylated by Rhes, reduced aggregation and enhanced cytotoxicity was observed. However, in 
both of these studies,72,73 aggregation was assessed by material that failed to enter a gel using SDS-
PAGE, and our analysis suggests that large, nonfibrillar aggregates comprised of SUMOylated htt 
may not be SDS stable. As a result, the distinct aggregate species we observe in vitro may not have 
been readily detected by these studies, and the enhanced toxicity associated with SUMOylation of 
htt may lie in the formation of these SDS-soluble aggregates. Modifying htt SUMOylation in the 
R6/2 mouse model of HD via reducing PIAS1, an htt-selective E3 SUMO ligase, results in altered 
phenotype.83,84 Increasing PIAS-1 improved behavioral phenotype; decreasing PIAS-1 
exacerbated phenotype.84 Inclusion formation may be a protective event, and the most toxic htt 
species, i.e. nanoscale oligomers and fibrils, remain diffuse throughout the cell.20–22,24,25 The 
increased cytotoxicity associated with SUMOylated htt may be due to the formation of these 
unique aggregates promoted by SUMOylation. 
 Many toxic mechanisms have been attributed to mutant htt, including nuclear DNA 
damage,68,114 transcription dysregulation,115,116 impairing function of other proteins via 
sequestration within aggregates,117,118 interference with central protein quality control and 
clearance mechanisms,119–121 alteration in endocytosis and microtubule-based transport,39 
disruption of cellular/subcellular membranes,10,59,61 and mitochondrial dysfunction.50,122 These 
varied mechanisms may act in a synchronistic manner in HD, or these toxic pathways may occur 
sequentially with one mechanism eliciting the next. Additionally, these different toxic mechanisms 
may be associated with distinct aggregate species within the complex htt aggregation landscape. 
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Such a scenario would account for the apparent conflicting reports trying to pinpoint specific toxic 
species. Here, a subpopulation of SUMOylated htt promoted β-sheet rich aggregates is introduced 
that appeared as oligomers and apparent larger conglomerates of these oligomers that were SDS 
soluble. As it has been noted that SUMOylation promotes neurodegeneration,72 this may be due to 
the promotion of diffuse β-sheet rich aggregates. While pointing specifically to fibrils, mutational 
modification of N-terminal fragments of htt was designed to control htt aggregation into 
predictable species.34 That is, constructs were designed that either quickly fibrilized despite having 
nonpathogenic length polyQ domains or formed stable α-helical oligomers. The constructs forming 
β-sheet rich fibrils were potently toxic in cell culture and drosophila models compared to α-helical 
oligomers, suggesting that the underlying amyloid structure is key to some toxic mechanism. 
As SUMOylation promotes β-sheet rich aggregates, the underlying toxic amyloid structure may 
be present in a distinct aggregate morphology, accounting for the enhanced toxicity 
by SUMOylation of htt. 
 As Nt17 mediates the interaction of htt-exon1 with lipid membranes, the impact 
of SUMOylation on the ability of htt to bind and disrupt TBLE bilayers was determined. There is 
precedent of SUMOylation of amyloid-forming proteins modifying protein interactions with lipids 
in cellular environments. In particular, SUMO regulates the sorting of α-syn into extracellular 
vesicles,123 and modification of oligodendroglial cell membranes by DHA followed by peroxide 
induced oxidative stress that promotes α-syn inclusions that are immunoreactive for SUMO1.124 
Many amphipathic α-helical lipid binding domains attach via a mechanism of initially inserting 
into short-lived defects in lipid membranes due to lateral diffusion of lipid components. This 
mechanism underlies the preference of many amphipathic α-helices to bind to curved 
membranes,125 and htt-exon1 displays a preference for curved membrane.126 Within Nt17, K6 and 
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K9 have been confirmed as major SUMOylation sites.83 Of these two lysine residues, K9 has been 
suggested to play a role in the initial binding of htt to lipid membranes.36 Attachment of the bulky 
SUMO protein to Nt17 likely provides a steric block to inserting into defects in lipid bilayers, 
preventing the ability to bind membranes. 
 Membrane degradation of the nuclear envelope, ER, and mitochondria has been attributed 
to mutant htt.10,59,127 The inhibition of lipid activity by SUMOylation suggests that enhanced htt 
toxicity associated with SUMOylation is not due to htt-induced membrane damage of organelles. 
As stated previously, there are a number of toxic mechanisms associated with mutant htt. While 
potentially preventing lipid interaction leading to membrane damage, SUMOylation may promote 
other toxic mechanisms. SUMOylation affects nucleocytoplasmic transport, resulting in the 
majority of SUMOylated proteins residing in the nucleus.128 Although this is quite 
speculative, SUMOylation may promote toxic mechanisms occurring in the nucleus, e.g. 
transcriptional dysregulation and DNA damage.115,129,130 Unraveling the role of distinct aggregate 
species and the interdependencies of htt-related toxic pathways will require careful temporal 
analysis of these processes within HD models. Interestingly, fluorescence correlation spectroscopy 
performed on htt-exon1-expressing PC12 cells provided temporal analysis of aggregate formation, 
revealing the early formation of oligomers with tetramers being the smallest species.12 With time, 
a number of higher ordered aggregates were detected, culminating in sedimentable htt aggregates. 
Temporally correlating DNA damage, caspase 3 induction, mitochondrial dysfunction, and cell 
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3. Oligomerization enhances huntingtin membrane activity but is suppressed by covalent 
crosslinking  
3.1. Abstract  
Huntingtin disease (HD) is a neurodegenerative disease caused by an expansion of a polyglutamine 
(polyQ) tract within the huntingtin (htt) protein. PolyQ expansion induces the self-assembly of htt 
into a variety of aggregate species ranging from small oligomers to large fibrils that eventually 
incorporate into large inclusion bodies. There is no general consensus on which of these aggregate 
states are responsible for toxicity of mutant htt. The first 17 amino acids of htt (Nt17), which 
directly precede the polyQ tract, play a role in initiating aggregation by facilitating the formation 
of oligomeric intermediates that lead to fibril formation. Nt17 also functions as a lipid membrane 
binding domain. Here to characterize the ability of different aggregate forms of htt to bind lipid 
membranes, htt was pre-aggregated, and the ability of specific aggregate species was determined 
by a polydiacetylene lipid binding assay. The aggregation state of htt was verified by atomic force 
microscopy (AFM). We find that, In Vitro, oligomers are the most active lipid binding species, 
while the lipid interaction was suppressed by the emergence of fibrils at the later time points. The 
possibility of oligomer stabilizing was investigated via a lysine crosslinker, DFDNB. The large 
dosage of DFDNB efficiently stabilized htt oligomers, eliminating its ability to further aggregate 
and interact with lipid membrane. Our data thus suggest the oligomers conformational flexibility 




Huntington’s disease (HD), a fatal neurodegenerative disorder, is one of many CAG repeat 
disorders.1,2 CAG repeats that exceed a critical threshold encode mutant polyglutamine (polyQ) 
domains that underlie the formation of a variety proteinaceous aggregates that are the hallmark of 
these diseases.3 In HD, the huntingtin protein (htt) contains the expanded polyQ domain within its 
first exon, and the critical threshold is ~35 repeats.4 Mutant htt is deposits as intranuclear and 
cytoplasmic inclusion bodies composed of fibrillar htt aggregates.5–7 Beyond these inclusions, htt 
aggregates into a numerous nanoscale oligomeric and fibrillar species that can be diffusely 
distributed in cells.3,8–12 While htt aggregation into fibrils is generally regarded to occur via a 
nucleus-dependent growth polymerization mechanism,13 the process can result in a complex 
mixture of distinct aggregate species, making it difficult to gain consensus on the prominent 
aggregate species involved in toxicity.  
Understanding the variety and mixture of htt aggregates and their physiological activity is 
important because these different species could be involved in an assortment of toxic mechanisms. 
Survival analysis of cultured neurons suggested that inclusion formation may be a protective event 
as maintaining a diffuse population of htt throughout the cell had a stronger correlation with 
death,14 and a poor correlation between inclusion body formation and toxicity is observed in 
cellular models of HD.15 However, inclusions have been directly implicated in cellular 
abnormalities associated with HD. For example, larger perinuclear inclusions of mutant htt induce 
cell death by direct disruption of the nuclear envelope,16 and inclusions impinge on the ER causing 
membrane deformation, local impairment ER organization, and alterations in ER membrane 
dynamics.17 Beyond the potential role of inclusion bodies, the diffuse cellular population of htt 
population is a heterogeneous mixture of monomers, oligomers, 9,18,19and fibrils.12,19,20 Nanoscale 
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diffuse aggregates can contain up to 1000–3000 molecules,8 and oligomeric species on the order 
of dimers and tetramers have been detected.10 Collectively, this underscores the vast array of 
potential htt aggregate species in the diffusion fraction. Evidence points to toxic gain of function 
of monomeric polyQ peptides,21 htt oligomers,19,22,23 and fibrils.24,25 With this in mind, it is 
possible that different htt aggregate species are associated with different toxic mechanisms 
associated with HD. 
Within htt-exon1, the polyQ domain is preceded on its N-terminal side by a seventeen 
amino acid sequence (Nt17) and by polyproline (polyP) and proline-rich regions on its C-terminal 
side. Both of these flanking sequences exert influence on htt aggregation. The addition of a 10-
residue polyP sequence to the C-terminus of a polyQ peptide impacts the underlying conformation 
of polyQ and aggregation rates.26–29 In particular, Nt17 mediates the initial interaction between htt 
exon1 monomers by self-association to form oligomers that aid in nucleation of fibrilliziation by 
bringing polyQ domains in to close proximity.26,30,31 At low concentrations, Nt17 appears 
intrinsically disordered.31,32 Upon interaction with a binding partner, Nt17 can adopt an 
amphipathic α-helical structure that facilitates oligomer formation and is observed in many htt 
aggregates to some degree.31,33,34 The ability of a peptide sequence to form an amphipathic α-
helices is often associated with binding lipid membranes with high curvature in a regulated 
manner.35 Nt17 functions as a lipid binding domain.32,36–40 These htt/lipid interactions can further 
modify aggregation, promoting distinct aggregation pathways in a membrane composition 
dependent manner.41–44 The interaction of htt with lipid membranes appears to also be polyQ length 
dependent.45,46  
Htt localizes and associates with a variety with membranous surfaces and organelles, 
including mitochondria, the endoplasmic reticulum (ER), the nuclear envelope, tubulovesicles, 
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endosomes, lysosomes, presynaptic and clathrin-coated vesicles, and the dendritic plasma 
membrane.6,16,47–51 These htt/lipid interactions often result in membrane abnormalities and 
disruption.16,51–53 In mouse models, brain lipids accumulate in htt aggregates and inclusions.54–56 
While these observations support a role for htt/lipid interactions in modifying the aggregaton 
process and ultimately HD pathogenesis, little is known concerning how htt aggregation state 
modifies the membrane activity of htt. Here, the impact of pre-aggregation of htt-exon1 on its 
ability to directly interact with lipid vesicles was determined. These analysis support the notion 
that oligomerization ehances the direct interaction between htt and lipid membranes and that 
fibrillization suppresses membrane activity. Within Nt17, there are three lysine residues that 
influence oligomerization and lipid binding.57–59 As a result, these lysine residues were targeted 
by 1,5-difluoro-2,4-dinitrobenzene (DFDNB) in an attempt to stabilize htt oligomers. While 
sufficiently large doses of DFDNB stabilized htt oligomers, this effectively negated their ability 
to interact with lipid vesicles, suggesting that oligomer flexibility may underscore their membrane 
activity.  
3.3.  Materials and Methods  
3.3.1. Expression and Purification of GST-htt-exon1 Fusion Protein 
Glutathione S-transferase (GST)-htt exon1 fusion proteins with pathogenic-length 
polyglutamine repeats (46Q) were expressed and purified as previously described.60 Briefly, the 
protein was expressed in Escherichia coli for 4 h at 37 °C and lysed. Proteins were purified using 
a BioRad low pressure liquid chromatograph equipped with a GST-affinity column. The purity 
and the relevant fractions were verified by SDS-PAGE. Relevant fractions were pooled and placed 
in dialysis at 4 °C for 2 days. To remove potential pre-aggregated species, the protein solution was 
centrifuged at (22,000 ×g for 30 min) before any experiments. Protein concentration was 
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determined by a Bradford assay. To initiate aggregation, the desired volume of protein solution 
was incubated with Factor Xa (Promega, Madison, WI). All experiments were carried out in a tris 
buffer (150 mM NaCl, Tris-HCl, pH 7.4). 
3.3.2. Atomic Force Microscopy (AFM) 
Ex situ atomic force microscopy (AFM) was used to characterize the morphology of htt 
aggregates. For pre-aggregation experiments, htt-exon1(46Q) (10 µM) were incubated 30 °C for 
and sampled after 1, 3, 5, and 8 h by taking a 3 µL aliquot and depositing it on freshly cleaved 
mica for 1 min. Then, the mica was rinsed with 150 µL of ultrapure water and dried with a gentle 
stream of air. For morphological analysis of crosslinked htt, aliquots were takend before 
crosslinking, immediately after crosslinking, and 24 h after crosslinking. Samples were imaged 
using a Nanoscope V Multi-Mode scanning probe microscope (VEECO) equipped with a closed-
loop vertical engage J-scanner. Silicon-oxide cantilevers with nominal spring constant of 40 N/m 
and a resonance frequency of 300 kHz were used. Scan rates were set to 1.99 Hz with cantilever 
drive frequencies at 10% off resonance. For in situ AFM experiments that tracked the interaction 
of htt with supported total brain lipid extract bilayers (TBLE), a tapping mode fluid cell equipped 
with an O ring and a cantilever with nominal spring constant of 0.1 N/m was used. The TBLE 
bilayer was prepared by reconstituting a lyophilized lipid film in the Tris buffer to a concentration 
of 1 mg/mL. The lipid solution then underwent 10 freeze-thaw cycles using liquid nitrogen 
followed by bath sonication for 10 minutes. The resulting lipid vesicle solution was injected into 
the fluid cell (30 µL), and the formation of the lipid bilayer was monitored by continuous AFM 
imaging (~2 h) until a complete 40 µm x 40 µm supported bilayer was formed. The bilayers were 
exposed to preformed oligomers, fibrils, or crosslinked oligomers by direct injection (20 µM of 30 
µL, resulting in a final concentration of 10 µM htt) into the fluid cell. Oligomers and fibrils were 
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prepared by 3 and 24 h of pre-incubation and verified via ex situ AFM. Crosslinked oligomers 
were prepared as described below. Morphological changes on the lipid bilayer were monitored by 
continuous imaging for 3 h. All images were analyzed using the Matlab image processing toolbox 
(MathWorks) as previously described.61  
 For in situ AFM experiments that tracked the interaction of htt with supported total brain 
lipid extract bilayers (TBLE), a tapping mode fluid cell equipped with an O ring and a cantilever 
with nominal spring constant of 0.1 N/m was used. The TBLE bilayer was prepared by 
reconstituting a lyophilized lipid film in the Tris buffer to a concentration of 1 mg/mL. The lipid 
solution then underwent 10 freeze-thaw cycles using liquid nitrogen followed by bath sonication 
for 10 minutes. The resulting lipid vesicle solution was injected into the fluid cell (30 µL), and the 
formation of the lipid bilayer was monitored by continuous AFM imaging (~2 h) until a complete 
40 µm x 40 µm supported bilayer was formed. The bilayers were exposed to preformed oligomers, 
fibrils, or crosslinked oligomers by direct injection (20 µM of 30 µL, resulting in a final 
concentration of 10 µM htt) into the fluid cell. Oligomers and fibrils were prepared by 3 and 24 h 
of pre-incubation and verified via ex situ AFM. Crosslinked oligomers were prepared as described 
below. Morphological changes on the lipid bilayer were monitored by continuous imaging for 3 h.  
3.3.3. Polydiacetylene Lipid Binding Assay 
A normalized polydiacetylene (PDA) lipid binding assay was utilized to measure the 
interaction between htt-exon1(46Q) and TBLE. Briefly, diacetylene monomers (10,12-
tricosadiynoic acid) and TBLE were dissolved in a 4:1 chloroform:ethanol solution and mixed at 
a 2:3 molar ratio. Solutions were dried under a gentle stream of nitrogen until a fully dried lipid 
film was formed. These films were reconstituted in hot tris buffer (150 mM NaCl, Tris-HCl, pH 
7.4, 70 °C), sonicated at 125 W for 10 min, protected from light, and left at 4 °C overnight to allow 
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vesicle formation. The following day, the diacetylene monomers in the lipid vesicles were 
polymerized by exposure to UV light (254 nm), resulting in a royal blue solution that undergo a 
colorimetric shift to red upon mechanical stress. PDA/TBLE solutions (400 µM) were incubated 
with different preparations of htt-exon1(46Q) at 30 °C, and the blue (650 nm) and red (500 nm) 
absorbance (Ablue and Ared respectively) were recorded every 5 min for 12 to 20 h. The negative 
control consisted of equal volumes of neat buffer and PDA/TBLE solution, while the internal 
standard involved equal volumes of 1M NaOH and PDA/TBLE. The NaOH creates repulsion 
between headgroups via protonation, causing a saturated colorimetric shift that can be used to 
normalize results.62 Additional controls with corresponding DFDNB/DTT concentration for each 




( × 100  (1) 
where PB is defined as Ablue/(Ablue + Ared) for the negative control (PB0) and sample condition 
(PB).  
3.3.4. Crosslinking htt with DFDNB  
 For crosslinking oligomers, htt-exon1(46Q) was incubated (after factor Xa treatment) at 40 
µm for 1 and 3 h on ice. Next, the htt samples were treated with varying concentration (2.5 to 20 
fold excess relative to final htt concentration of 20 µM) of DFDNB. After mixing by inversion, 
the crosslinking interaction ran for 10 min at 20 ºC. After which, the reaction was quenched by 
equimolar concentration of dithiothreitol (DTT). 10 min after the addition of DTT, the solutions 
were used in PDA or ThT assays. All crosslinked htt reactions were characterized by ex situ AFM 
analysis.  
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3.3.5. Thioflavin-T Aggregation Assay (ThT) 
 Thioflavin T fluorescence assays (ThT, Sigma-Aldrich, St. Louis, MO) were performed to 
monitor fibril formation. Experiments were performed in multi-well plate format (Costar clear-
bottom 96-well plates) using a SpetraMax M2 microplate reader (440 nm excitation, 484 nm 
emission) with readings taken every 5 min for 15 h. The ThT concentration in each well was 200 
µM. Experiments were performed in Costar clear-bottom 96-well plates at 37 °C and ThT. Each 
experiment was performed three separate times, and within each experiment individual conditions 
were run in triplicate. Controls included neat buffer and corresponding concentration of 
DFDNB/DTT for each condition used for oligomer crosslinking.  
3.3.6. Dynamic light scattering  
 Dynamic light scattering (DLS) was used to measure the size distribution of the htt control 
and crosslinked htt after 24 h, 3 days, and 10 days after the crosslinking reaction. DLS experiments 
were performed on a 90Plus/BI-MAS nanoparticle size analyzer (Brookhaven instrument). The 
wavelength of the laser was 635 nm and the scattered light was measured at 90°. Htt samples were 
diluted to a final concentration of 4 µM. Due to the formation of larger aggregates in the htt control 
(non-crosslinked) samples and crosslinked htt with 5 x DFDNB treatment, a high speed centrifuge 
step (5,000 g) for 20 min was required to pellet the larger size particles and allow the suspensions 
to be in the size limit range of the instrument. Measurements were taken at 25 °C, and the data was 
analyzed using the MAS OPTION software. 
3.3.7. MTT toxicity assay  
 The cytotoxicity of htt oligomers, DFDNB crosslinker and, crosslinked oligomers was 
tested on the Neuro-2a (N2a) cell line (ATCC® CCL-131™) using Mitochondrial 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction assay. The oligomers 
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were prepared with 3 h incubation of htt-exon1(46Q) on the ice at a concentration of 20 µM. In 
the following step, oligomers were crosslinked with 20x or 5x DFDNB treatments under the same 
condition prescribed before. The crosslinked reactions were quenched by the equimolar 
concentration of DTT after 10 min. The final concentration of the oligomers in the crosslinked 
solutions were 10 µM. Samples of DFDNB solutions corresponding to 200 µM were prepared to 
measure the toxic potency of the free DFDNB crosslinker. To reduce the excess free DFDNB 
molecules, crosslinked oligomers and DFDNB solutions were dialyzed for 24 h with (300 µL of 
sample to 10 mL of dialysis buffer), and the dialysis buffer was exchanged three times. On the day 
of experiment, fresh htt oligomers at a concentration of 10 µM were prepared to be used as a 
control.  
 In the next step, stabilized oligomers, freshly non-crosslinked oligomer controls, and 
DFDNB vehicle controls were added to the extracellular medium of cultured N2a cells plated in 
triplicate in a flat-bottom 96-wells microplate. The samples were added via serial dilution resulting 
in doses ranging from 0.2 µM to 5 µM final concentration of htt in the wells. The DFNDB 
concertation of the vehicle control in the wells varied from 0.2-0.08 µM based on equivalent 
volume added for the htt samples. To facilitate transferring the oligomers, cells were permeabilized 
with 0.1% saponin prior to the experiment, and the MTT assay was performed 72 h after the 
addition of htt. At this time, the MTT assay was performed as described in the MTT assay kit 
protocol (Millipore Sigma).  
3.4. Results 
3.4.1. Htt oligomer formation correlates with lipid binding 
 While the ability of htt-exon1 to directly bind and interact with lipid membranes is well 
established, little is known concerning the role of aggregation state on this process. To gain an 
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initial understanding of how aggregation state impacts the ability of htt to bind lipids, 10 µM htt-
exon1(46Q) samples were pre-incubated at 30 °C for variable lengths of time (1, 3, 5, and 8 h), 
allowing aggregation to proceed to varying extents. For these different htt incubations, aliquots 
were then taken to analyze the population of aggregates via ex situ AFM (Fig 3.1A). Htt oligomers 
were observed after 1 h of incubation; whereas, fibrils were not observed until the 5 h time point.  
 
Fig 3.1 (A)Ex situ AFM images of htt-exon1(46Q) aggregates present after 1, 3, 5, or 8 h of incubation at 
10 µM. The second color bar (labeled in blue) corresponds to the insets in the images marked by blue 
boxes. (B) Analysis of oligomer and fibril populations present at each time point. (C) Histograms of 
oligomer height and diameter as a function of time. (D) PDA/TBLE lipid binding assay performed with htt-
exon1(46Q) pre-incubated for various length of time. (E) The maximum PDA signal plotted as a function 
of the oligomers per unit area observed by AFM. Error bars represent standard deviation taken across 
multiple images and experiments. 
 To further assess the aggregate populations associated with different incubation times, 
automated algorithm measured morphological features of all aggregates in AFM images, and 
specific criteria were used to determine the number of oligomers. Oligomers were defined as 
particle taller than 1 nm with an aspect ratio of less than 2.5, indicating a globular structure. Due 
to extensive bundling, the fibril population was determined by visual inspection of all images. The 
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number of oligomers and fibrils per µm2 was determined (Fig 3.1B). A substantial number of 
oligomers were observed after 1 h of incubation (17.0 ± 1.5 per µm2), and the oligomer population 
peaked (23.2 ± 1.4 per µm2) after 3 h. With longer incubation times, the oligomer population 
steadily decreased (17.9 ± 2.5 per µm2 and 8.4 ± 3.1 per µm2 at 5 and 8 h respectively). This 
decrease in oligomer population occurred concurrently with a rise in the fibril population. While 
oligomers were present at each incubation length, there were morphological differences observed 
at each time points. After 1, 3, and 5 h of incubation, oligomers had a mode height of ~3.5-4.5 nm 
and a mode diameter of ~60-70 nm (Fig 3.1C). However, a distinct tail in the diameter histogram 
developed with increasing incubation time. After 8 h of incubation, oligomers shifted to a clearly 
larger size (mode height of ~5-6 nm and a mode diameter of ~80-100 nm).  
Having characterized the htt aggregate populations associated with different incubation 
conditions, the extent to which the different incubations interacted with a total brain lipid extract 
(TBLE) bilayer was determined via a polydiacetylene (PDA) lipid binding assay (Fig 3.1E). 
TBLE/PDA vesicles are initially blue but mechanical stress applied to the PDA backbone by 
protein binding to the lipid component induces a quantifiable colorimetric response (CR). To 
enable comparison between unique experiments, the CR for a given batch of TBLE/PDA vesicles 
was normalized to a maximum CR determined by exposing the vesicles to a large dose of NaOH.63 
Addition of neat buffer was used as a negative control. These vesicles were then exposed to 10 
µM preparations of htt-exon1(46Q) that had been incubated for various lengths of time, resulting 
in unique aggregate profiles. Upon exposure of PDA/TBLE vesicles to freshly cleaved htt-
exon1(46Q) (0 h incubation, predominately monomeric), a steady increase in the PDA signal was 
observed, maxing out at ~ 15.9% relative intensity after 12 h (Fig 3.1D). The 1 h incubation that 
contained oligomers elicited a significantly large CR, reaching 22.3% relative intensity. The 3 h 
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incubation, which contained the largest oligomer population, invoked the largest PDA signal with 
a maximum value 26.9% relative intensity. The PDA signal produced by the 5 h incubation was 
less intense compared to the 3 h incubation, maxing out at 23.7%. Interestingly, the oligomer 
population was comparable between the 1 and 5 h incubations, and the invoked PDA signals were 
also similar. However, the 5 h incubation contained a substantial fibril population as well. Lastly, 
the 8 h htt incubation, which contained fewer oligomers and more fibrils, resulted in an even 
greater reduction in the PDA signal (maximum of 19.0%). The maximum PDA signal correlated 
linearly with the oligomer population size (Fig 3.1E, R2 = 0.97), suggesting that oligomerization 
enhances the ability of htt to bind membranes.  
A complication of the previous analysis is that these incubations still contained complex 
mixtures of htt monomers and aggregates. That is, as fibrils were not the predominate specie in 
any of the incubation, the relative fibril affinity for membranes was difficult to assess. Therefore, 
a TBLE/PDA assay was performed with freshly prepared (predominately monomeric) htt, 
oligomeric htt, and fibrillar htt at a final concentration of 10 µM for all three conditions (Fig 3.2). 
To obtain oligomers, htt was incubated on ice for 3 h. To obtain a predominately fibrillar sample, 
htt-exon1(46Q) was seeded (0.25 µM concentration) with preformed fibrils of a polyQ peptide and 
incubated for 24 h at 30°C. Prior to the TBLE/PDA assay, the htt samples were checked by ex situ 
AFM to verify that the appropriate aggregate species were present (Fig 3.2A). The freshly prepared 
sampled contained a few oligomers but significantly fewer compared to the oligomeric prep. The 
fibril sample contained long, entangled fibrils. The oligomer prep elicited the largest CR from the 
TBLE/PDA assay, an ~3-fold increase in maximum signal compared with fresh htt (Fig 3.2B). Htt 
fibrils induced the smallest relative CR with a maximum signal that was significantly reduced 
(~45% reduction) compared to oligomers. This further supports that oligomers have large 
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membrane activity compared with either htt monomers or fibrils and that fibrils are the least 
membrane active species.  
 
Fig 3.2 (A) Ex situ AFM images of different preparations of htt-exon1(46Q) aggregates (freshly htt, 
oligomers, and fibrils) that were used for (B) PDA/lipid binding assays. 
3.4.2. Crosslinking oligomers alters htt aggregation in a dose-dependent manner  
Having established that htt oligomers have a relatively large membrane activity, the 
possibility of stabilizing oligomers via chemical cross-linking was explored. As Nt17 promotes htt 
aggregation via an α-helical oligomeric intermediate, it represents a viable target for oligomer 
stabilization. There are three lysine residues located within Nt17, two (K6 and K15) of which are 
implicated in oligomer formation. As a result, a lysine specific cross-linking agent, 1,5-difluoro-
2,4-dinitrobenzene (DFDNB)64–67, was employed to crosslink htt oligomers. DFDNB cross-linking 
is an established method of stabilizing oligomers of other amyloid-forming proteins.67 To establish 
conditions for oligomer stabilization, DFDNB was applied to htt incubations after 1 or 3 h at 
various doses ranging from 2.5× to 20× DFDNB to the final htt concentration of 10 µM. The 
crosslinking reaction was allowed to proceed for 10 min and then was quenched with DTT. To 
monitor the ability of the different crosslinking conditions to arrest fibril formation, Thioflavin T 
(ThT) assays were starting as soon as the DFDNB crosslinking reaction was quenched (Fig 3.3A-
B). Control htt-exon1(46Q) incubations that were only treated with vehicle (no DFDNB) that had 
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been incubated for 1 h invoked a continuous increase in ThT fluorescence over 15 h (Fig 3.3A). 
Similarly, control htt-exon1(46Q) that had been pre-incubated for 3 h continued to invoke a ThT 
signal, reaching a steady-state phase at ~12 h (Fig 3.3B). Upon covalent crosslinking after 1 h of 
pre-incubation htt with doses of 2.5× and 5× DFDNB, the rate of aggregation was actually 
enhanced compared to control. DFDNB treatments of 10×, 15×, or 20× after 1 h of pre-incubation 
suppressed htt aggregation, with the 10× dose being slightly less effective. When htt was treated 
with different doses of DFDNB after 3 h of pre-incubation, only the 2.5× treatment enhanced 
aggregation. Doses of 5× DFDNB or higher suppressed fibrillization; although, a slight increase 
in ThT signal was observed for 5× and 10× towards the end of the assay.  
While ThT assays suggested that larger doses of DFDNB could effectively suppress 
fibrillization, oligomer stabilization was further validated using ex situ AFM. This will allow for 
visualization of oligomeric species and comparison of their morphological features. Aliquots were 
taken from untreated and crosslinked htt-exon1(46Q) samples that had been pre-incubated for 3 h 
immediately after DFDNB treatment and after an additional 24 h of incubation for AFM analysis. 
In the control incubation, abundant oligomers were present at the 3 h time point (Fig 3.3C). After 
an additional 24 h of incubation, the control htt sample was comprised of oligomers and an 
extensive network of fibrils. All of the crosslinked samples appeared similar to control at the 3 h 
time point; that is, there was an extensive oligomer population. 
After an additional 24 h of incubation, htt-exon1(46Q) that was treated with 2.5× DFDNB 
had formed a significant number of fibrils (Fig 3.3D), consistent with the ThT assay. These fibrils 
often appeared to be thicker than control fibrils with a slightly curved, less rigid appearance. Larger 
DFDNB treatments (5× or higher) suppressed fibril formation and appeared to stabilize oligomers 
after 24 h of additional incubation; although, a few small protofibrils were observed with 5× and 
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10× doses of DFDNB (Fig 3.3D), which may account for the slight increase in ThT signal 
observed. 
 
Fig 3.3 ThT assay tracking aggregation of htt crosslinked after (A) 1 h of pre-incubation or (B) 3 h of pre-
incubation. (C) AFM images of htt without crosslinking after 3 and an additional 24 h of incubation. (D) 
AFM images of htt, which was crosslinked with varying doses of DFDNB after 3 h of pre-incubation, 
imaged after an additional 24 h of incubation. Green circles indicate small protofibrils. For both C and D, 
the second color bar (labeled in blue) corresponds to the insets in the images marked by blue boxes. (E) 
Correlation plots of height vs diameter of oligomers taken before crosslinking and an additional 24 h after 
crosslinking. In addition, the height (top) and diameter (right) histograms are provided.  
Next, the morphological features of oligomers were measured at the 3 h crosslinking 
timepoint and compared to the morphologies after 24 h of additional incubation (Fig 3.3E). 
Comparison of diameter/height correlations and histograms indicates that the morphology of 
oligomers treated with high doses of DFDNB (10× or higher) were unaltered with additional 
incubation. However, oligomers treated with 5× DFDNB had a slight shift to larger heights.   
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To further validate oligomer stabilization by DFDNB, a series of DLS experiment were 
performed. Oligomers were crosslinked after 3 h of pre-incubation with 5×, 10×, 15×, or 20× 
DFDNB. An additional solution without crosslinking was also prepared. After 3 days of additional 
incubation, size distributions of each sample were measured by DLS (Fig 3.4A). The control and 
5× crosslinked samples diameter distribution was not consistent with oligomers as the mode size 
was well over 1 µm for both. In fact, these samples required a high-speed spin to pellet larger 
aggregates so that the remaining aggregates were within the size limits of the instrument. When 
crosslinked with DFDNB treatments of 10× or higher, the mode diameter of aggregates was ~40-
70 nm, consistent with the oligomers observed by AFM. These samples treated with 10× DFDNB 
or higher were incubated for an additional week (10 days after initial crosslinking), and the size 
distributions for all three samples were remarkably similar to those measured after 3 days of 
additional incubation, validating the long term stability of these crosslinked oligomers (Fig 3.4B-
D). 
 
Fig 3.4 (A) Comparison of aggregate diameter measured by DLS for non-crosslinked and crosslinked htt 
(after 3 h of pre-incubation) with varying doses of DFDNB after an additional 3 days of incubation. 
Comparison of aggregate diameter of htt oligomers crosslinked after 3 h of pre-incubation with (B) 10x, 
(C) 15x, and (D) 20x DFDNB treatments after 3 and 10 days of additional incubation. 
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3.4.3. Crosslinking inhibits the ability of oligomers to bind to lipid vesicles  
Having established that htt oligomers had the highest membrane activity in comparison to 
monomers or fibrils, the membrane activity of DFDNB crosslinked oligomers was determined 
using the TBLE/PDA assay (Fig 3.5A). After 3 h of incubation, htt oligomers were crosslinked 
with DFDNB treatments ranging from 2.5× to 20×. Backgrounds were accounted for in the 
calculation of the %CR, and the signal was again normalized to a maximum CR associated with a 
controlled dose of NaOH. As a control, TBLE/PDA vesicles were exposed to untreated htt 
oligomers, and a large CR was observed (maximum signal of ~60%). The membrane activity of 
oligomers was reduced by cross-linking in a DFDNB dose dependent manner. Treatment with 2.5× 
DFDNB reduced the relative signal intensity associated with exposure to oligomer by ~10%. 5× 
DFDNB clearly slowed the membrane activity of oligomers, and the maximum relative signal 
reached after 20 h was cut by half compared to the untreated control. A small CR was associated 
with oligomers treated with 10× DFDNB, reaching a maximum relative CR of ~12%. Oligomers 
stabilized by 15× and 20× appeared to have virtually no membrane activity. Collectively, this 
suggests that stabilizing htt oligomer with DFDNB suppresses their ability to interact directly with 
lipid membranes (Fig 3.5A) 
 To further evaluate the membrane activity of oligomer (both stabilized and untreated) and 
fibrils, a series of in situ AFM experiments were performed to visualize morphological changes 
on supported TBLE bilayers upon exposure to different htt aggregate species (Fig 3.5C). The 
formation of a supported bilayer was achieved by direct injection of vesicles into the AFM fluid 
cell, and these were allowed to fuse on the mica surface with continuous monitoring by AFM 
imaging. Once a large (40x40 µm), hole-free bilayer was formed, different htt preparations were 
directly injected into the fluid cell to a final protein concentration of 10 µM. These htt preparations 
included 1) htt oligomers obtained by 3 h of pre-incubation before injection into the fluid cell, 2) 
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htt oligomers crosslinked with 20× DFDNB after 3 h of pre-incubation, and 3) fibrils 24 h 
incubations that had been seeded. All three preparations were sampled for ex situ AFM verification 
of the aggregates present (Fig 3.5B).  
 
Fig 3.5 (A) The relative lipid binding affinity of htt oligomers that were pre-incbuated for 3 h without and 
with varying treatments of DFDNB crosslinking. (B) Ex situ AFM images of htt oligomers (formed after 3 
h of incubation), fibrils (formed by seeding and 24 h of incubation), and crosslinked oligomers (3 h of pre-
incubation). (C) Time course in situ AFM images of a supported TBLE bilayer exposed to htt oligomers, 
fibrils, and crosslinked oligomers.  
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Within 30 minutes of injection, numerous htt oligomers appeared on the bilayer surface that were 
sometimes associated with what appeared to be small holes in the bilayer. With time, regions of 
increased bilayer roughness developed on the bilayer and grew. These regions were often (though 
not always) associated with the presence of an oligomer. In the absence of lipids, fibrils are 
typically observed in incubations of htt-exon1(46Q) at this concentration in this time frame (a total 
of 6 h). However, no fibrils were observed on the bilayer surface, consistent with reports that 
TBLE inhibits htt fibrillization. With pre-formed fibrils, bilayer morphology was subtly altered in 
some regions, and this occurred to a lesser extent in comparison to experiments with untreated 
oligomers. Again, no fibrils appeared on the surface, but a few oligomers were observed, which 
may represent residual oligomers left over in the sample prep. When exposing TBLE bilayers to 
stabilized htt oligomers very few (if any) crosslinked oligomers bound to the surface, and the 
bilayer morphology was not altered over the entire 3 h timeframe. The disrupted membrane regions 
invoked by untreated oligomers or fibrils were morphologically different. As demonstrated by 
height profiles (Fig 3.6A), untreated oligomers tended to invoke larger and rougher regions of 
disruption. The TBLE bilayer morphology observed upon exposure to DFDNB stabilized 
oligomers was comparable to freshly formed TBLE bilayers.  
To better quantify this, the RMS roughness of the TBLE bilayer was measured as a function of 
time. To avoid artifacts in these measurements associated with surface coverage of these regions, 
two RMS roughness values were determined for samples that contained disrupted bilayer regions, 
one for the disrupted regions (rough) and one for the undisrupted regions (smooth). If perturbed 
regions were not identified, RMS values were measured across the entire image (Fig 3.6B).  A 
freshly formed bilayer had an RMS roughness typically smaller than 0.4 nm indicating a smooth 
bilayer. Upon exposure to untreated htt oligomers, rough regions of RMS roughness were 1.9 ± 
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0.3 nm after 30 min. The RMS roughness appeared to increase with time (2.8 ± 0.9 nm at 3 h). 
The disrupted bilayer regions observed upon exposure to pre-formed fibrils were less pronounced 
with RMS roughness values falling between 0.6 and 0.9 nm, which was still significantly larger 
than a fresh TBLE bilayer. For exposure to both untreated oligomers and pre-formed fibrils, the 
undisrupted (smooth) portions of the bilayer had RMS roughness values similar to a freshly 
prepared bilayer. DFDNB oligomers did not disrupt a large enough portion of the bilayer to obtain 
meaningful RMS values of rough areas; however, the RMS roughness measured over the entire 
image for all time points was indistinguishable from a fresh TBLE bilayer.  
To quantify the extent of bilayer disruption by the different htt samples, pattern recognition 
algorithms were used to identify regions of the bilayer morphology that were disrupted or 
unperturbed, allowing for the percentage of the bilayer surface disrupted to be determined as a 
function of time (Fig 3.6C). After 30 min of exposure to untreated htt oligomers, 0.9 ± 0.2 % of 
the bilayer surface was disrupted, and the extent of disrupted bilayer steadily increased with time, 
reaching 10.7 ± 1.6% within 3 h. Fibrils disrupted the bilayer to a significantly lesser extent, with 
only 4 ± 0.4% of the bilayer being altered after 3 h. DFDNB Crosslinked oligomers did not induce 
extensive membrane disruption over 3 h. The % area disrupted was less than 1% at each time point, 
and these regions were predominately discrete oligomers appearing on the surface rather than 




Fig 3.6 (A) Comparison of the morphology of supported TBLE bilayers exposed to oligomers, fibrils, or 
DFDNB stabilized oligomers. The colored lines in each in situ AFM image corresponds to the height 
profiles provided to the right. In each height profile, the gray shaded areas correspond to regions of the 
bilayer with increased surface roughness. (B) Comparison of the RMS roughness associated with a TBLE 
bilayer and the smooth and rough regions observed after exposure to htt oligomers, fibrils, and DFDNB 
stabilized oligomers as a function of time. As rough regions in the bilayer did not develop upon exposure 
to DFDNB stabilized oligomers, RMS roughness was measured over the entire image. (C) Comparison of 
the % area of the TBLE bilayer that was disrupted by exposure to htt oligomers, fibrils, and DFDNB 
stabilized oligomers as a function of time. For both B and C, the error bars represent standard deviation 
across three independent experiments. 
3.4.4. Crosslinking reduces oligomer toxicity  
 To determine of DFDNB crosslinking altered htt oligomer toxicity, an MTT cytotoxicity 
assay was performed on N2a neuronal cultured cells. These cells were exposed to freshly prepared 
htt-exon1(46Q) oligomers, DFDNB stabilized oligomers (5x and 20x treatments, and a DFDNB 
vehicle control). The unmodified and crosslinked oligomers were added to the culture medium in 
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doses ranging from 0.2-5 µM final concentration in the wells. To aid in uptake of the htt oligomers, 
the cells were permeabilized with saponin.68,69 The concentration of DFDNB in vehicle controls 
ranges at a maximum ~0.008 µM to 0.2 µM based on the amount needed to crosslink the htt 
oligomers at 20x, dilution by dialysis, and the final volume added to each well. Complicating the 
assay, DFDNB itself was toxic to cells. Exposure to 0.3 µM or higher DFDNB reduced cell 
viability to less than 23 % relative to control (N2a cells not exposed to htt or DFDNB); however, 
cell viability was 67.3 ± 4.0 % with exposure to 0.12 µM DFDNB (corresponding to the 0.2 µM 
htt concentration).  
Unmodified htt-exon1(46Q) oligomers (no DFDNB) were toxic to N2A cell in a dose 
dependent manner (Fig 3.7). Cell viability was 15.8 ± 1.0 % relative to control with 5 µM doses 
of unmodified htt oligomers, and this increased to 40.4 ± 3.6 % upon exposure to unmodified htt 
oligomer at 0.2 µM. With stabilized oligomers treated with 5x or 20x DFDNB, there was not a 
significant change in cell viability at doses greater than 1.5 µM; although, there is a trend of 
increased viability relative to control with as the concentration decreases. The issue in interpreting 
this result is that there is toxicity associated with untreated htt and residual DFDNB. With exposure 
to 0.5 µM stabilized oligomers, there is a not quite statistically significant (p < 0.05) increase in 
cell viability (39.1 ± 5.5% relative to control) with 5x DFDNB stabilized oligomers, and both 5x 
(96.8 ± 4.3% cell viability) and 20x (75.7 ± 4.8% cell viability) treated DFDNB oligomers are 
significantly less toxic (both have p < 0.01 compared to untreated htt oligomers). With regard to 
the 20x DFDNB treated oligomers, the cell viability mirrored closely the viability observed with 
the DFDNB alone control. In short, unmodified htt (no DFDNB added) considerably reduced cell 
viability with doses as low as 0.2 µM. Vehicle control containing DFDNB (but no htt) reduced 
cell viability as well, potentially masking the impact of DFDNB treatment on htt oligomer toxicity 
 96 
at high protein concentrations. However, as the DFDNB was effectively diluted out with smaller 
doses of htt, DFDNB treated oligomers became less toxic relative to htt control. A plausible 
explanation is that crosslinking reduces oligomer toxicity, but crosslinking also removes free 
DFDNB from solution, effectively reducing DFDNB toxicity as well. As a result, as residual 
DFDNB toxicity is removed, it becomes clearer the crosslinked htt oligomers are less toxic than 
their unmodified counterparts, suggesting a loss in membrane activity results in a corresponding 
reduction of htt-induced toxicity. 
 
Fig 3.7 MTT toxicity assay for the N2a cells exposed to oligomers and crosslinked oligomers with 5x and 
20x DFDNB treatment. * indicates p < 0.05, ** indicates p < 0.01 based on a t test (n = 3). Error bars 
represent standard error of the mean (SEM). 
3.5. Discussion 
Mutant htt is implicated in structural abnormalities and dysfunction of a variety of 
membranous organelles.6,70–73 While damage to a variety of subcellular membranes is evident in 
HD, little is known regarding how specific aggregate species interact with lipid membranes. Here, 
the membrane activity of various aggregation states of htt was determined, which implicated 
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oligomer of being particularly potent in binding lipids. Extensive fibril formation dramatically 
reduced the ability of htt to directly interact with membranes. Having established the membrane 
activity of htt oligomers, a crosslinking strategy was employed to stabilize these aggregate species. 
Due to the role of lysine residues in aggregation and oligomer structure,34,59 a known lysine specific 
crosslinking agent, DFDNB, was used. Rather than stabilizing oligomers, small doses of DFDNB 
could accelerate fibrillization, but with larger doses oligomer stabilization was achieved. However, 
stabilization precluded membrane activity and reduced cytotoxicity of the htt oligomers. 
Collectively, these results suggest some sort of conformational flexibility underlies the membrane 
activity of htt oligomers and that targeting structural features of htt oligomers represents a strategy 
to block their ability to disrupt membranes, reducing oligomer cytotoxicity. 
Lipid membranes are known modulators of htt aggregation.41,44,74 However, fibril can be 
either stimulated41,48 or reduced36,42,43,46,57,74 by membranes depending on the precise lipid 
composition. Membrane activity of htt-exon1 is facilitated by Nt17,36,37,75 and mutant htt disrupts 
a variety of organelle membranes, leading to their dysfunction.16,48,51,76,77 Beyond this, distinct htt 
aggregates are linked to specific membrane abnormalities. For example, htt inclusions impinge 
upon the ER17 and the nuclear envelope16 leading to altered membrane dynamics, deformation, 
and disruption. While these studies associated htt fibrils/inclusions with changes in ER membranes 
or the nuclear envelope, this may represent a late stage marker of earlier events, as it is plausible 
that subtle alterations in these membranes are induced by earlier htt aggregates or even the 
aggregation process. Such a notion is supported by the ability of un-aggregated mutant htt to 
invoke localized morphological and mechanical changes on model lipid membranes36,46,78 and our 
observation reported here that fibrils have significantly reduced membrane activity. In addition, 
N-terminal fragments of mutant htt, such exon1 preferentially segregated to membrane fractions 
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in HD brains.79 Htt oligomers have been associated with inducing mitochondrial fragmentation 
and ER stress.50,80  
With regard to oligomers having larger membrane activity in comparison to monomeric or 
fibrillar htt, a plausible mechanism involves availability of induced α-helical structure of Nt17 (Fig 
3.8A). The Nt17-mediated htt membrane binding involves four basic steps: approach, 
reorganization, anchoring, and insertion.81 In short, an intrinsically disordered Nt17 stabilizes its 
interaction with lipid membranes by folding into an amphipathic α-helix. In the time it takes for 
reorganizing into an α-helix, there is a chance that Nt17 could dissociate from the lipid bilayer.57 
Nt17’s ability to form amphipathic α-helices promotes inter-protein association into oligomeric 
intermediates that enhance fibril formation.30,31 Structurally, htt tetramers pack into α-helical 
bundles of Nt17 in an antiparallel fashion.34 In solution, Nt17 exists in a concentration-dependent 
equilibrium between an intrinsically disordered monomeric state and these α-helical 
oligomers.26,31,82 The stabilization of the Nt17 α-helix by oligomerization may bypass the 
reorganization step, enhancing the membrane activity of oligomers. Such a mechanism requires 
two assumptions: 1) that preformed α-helixes indeed bind faster and 2) that oligomer structures 
are flexible enough for Nt17 α-helices to be available for interaction with lipids. Computational 
studies support the first assumption as preconfiguring Nt17 into α-helixes speeds up the interaction 
between Nt17 and lipids.83 The second assumption is supported by our observation that cross-
linking oligomers, and thus reducing their conformational flexibility, leads to a loss of membrane 
activity.  
With regards to fibrils being less membrane active, this is likely due to availability of Nt17 
in the fibril structure. Htt fibrils are comprised of a rigid amyloid core of polyQ domains.84–86 This 
core is surrounded by both the Nt17 and proline-rich domains (PRD). While there is some 
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variations from different studies, the PRD appears to be more flexible and solvent exposed of the 
two flanking regions in the fibril structure.84,87–89 In reported fibril structures, the dynamics and 
conformation of Nt17 varies, ranging from being completely buried in a packed structure,88 to 
dynamic heterogeneity with partially dynamic residues,87 or to being helical with partial 
immobilization by dense packing of flanking sequences on the fibril surface.33,84,90 In our study, 
decreased lipid binding affinity of pre-aggregated htt fibrils most likely support the notion that 
Nt17 domain is either not accessible within mature fibrils or at least is partially bracketed with 
non-helical structure that restrict initial binding and further insertion of htt fibrils into lipid 
membrane. Molecular dynamic studies suggest that the polyQ region forms hydrogen bonds with 
the phospholipid head groups, providing a scaffold for further insertion of Nt17 into the lipid 
membrane core.81 The unavailability of polyQ to function in this capacity due to dense packing in 
the amyloid core would also reduce the membrane activity of fibrils. Collectively, the differences 
in membrane activity between oligomers and fibrils suggests a key role of structural flexibly in 
htt/lipid interactions. 
While high doses of DFDNB crosslinker stabilized oligomers, it was surprising that low 
doses accelerated fibrillization. As both intra and intermolecular crosslinking occurs with DFDNB, 
such a strategy results in an inherent complexity of crosslinking products.91–96 DFDNB-modified 
lysine residues may initially serve as intermediates which either interact with another lysine 
residue intermolecularly or intramolecularly. Low concentration of DFDNB relative to the target 
substrate promotes intramolecular crosslinking; whereas, efficiency of intermolecular crosslinking 
is enhanced with higher DFDNB doses.94 With this in mind, it should be noted that with three 
lysine residues in Nt17 that lower doses of DFDNB resulted in an excess of target residues, which 
would promote intramolecular crosslinking. Based on acetylation studies, lysine 9 appears to be 
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the most readily available lysine residue for modification.57,97 As a result, it represents the most 
likely modified lysine residue with lower doses of DFDNB. Based on available structural analysis 
of Nt17 derived oligomers, lysine 9 is not involved in structural stabilizing intermolecular 
interactions34,59,98 and would not be well positioned to be involved in intermolecular crosslinks. 
However, there is the potential to form intramolecular crosslinks between lysine 9 and lysine 6, 
which would be relatively close in space within an α-helix, with an approximate separation 
distance of 3-4 Å that correlates well with the DFDNB arm length of ~3.5 Å. Lysine 9 and lysine 
15 would be further spaced apart. Such an intramolecular crosslink could push the equilibrium 
between disordered Nt17 monomers and higher order multimers toward oligomerization without 
restricting conformational freedom needed for initiating fibrillization. Such a scenario may 
underlie the observed enhanced fibril formation with low doses of DFDNB. With larger DFDNB 
treatments, intermolecular crosslinks associated with lysine 6 and 9 form, stabilizing oligomers. 
While a clear consensus of the fate of Nt17 in fibrils is lacking,99 forming the densely packed 
polyQ amyloid core likely requires some conformational flexibility within the Nt17-mediated 
oligomer intermediate, which a high density of intermolecular crosslinks restricts. The necessity 
of such a structural transition represent the rate limiting step in which fluid oligomeric complexes 
undergo stochastic rearrangement to nucleate fibril formation in the yeast prion protein Sup35.100 
With low doses of DFDNB that promoted fibril formation, the partial reduction of 
membrane activity by non-stabilized oligomers may encompass a variety of mechanisms. By 
promoting aggregation, the highly membrane active oligomer population would be reduced as 
membrane inactive fibrils form. In addition, it is possible that nucleophilic substitution of fluorine 
atoms of DFDNB to the primary amine of lysine residues101 within Nt17 removes cationic 
character that mediates lipid binding.37,38,57,74,81 With higher doses of DFDNB, conformational 
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flexibility of α-helical bundles is compromised by intermolecular DFDNB-mediated crosslinking 
of lysine residues, and the membrane activity of stabilized oligomers is completely inhibited (Fig 
3.8B). This is likely due to abundant intermolecular crosslinks that stabilized htt oligomers but 
suppresses the conformational flexibility required for binding lipid membranes, in the same 
manner by which these crosslinks prevent fibril formation. 
Despite years of studies, the precise molecular mechanism of htt aggregation and its 
realation to cellular toxicity is not completely understood. The temporal emergence of various 
aggregate states has been linked to numerous pathological events associated with mutant htt. While 
initially inclusions were thought to be toxic species, 5,70 diffusely distributed htt within the cell 
correlates well with toxicity.14,15 This diffusely distributed htt, however, is comprised of a 
heterogeneous mixture of monomers, oligomers, and fibrils.11,12,102–104  
 
Fig 3.8 The proposed mechanism for interaction of (A) oligomers and (B) crosslinked oligomers with lipid 
membrane  
This complexity, along with the metastability of many aggregate intermediates, has made precise 
assignment of toxic gain of function to specific aggregate species difficult. In addition, the 
transient nature of aggregate intermediates has impeded their structural characterization needed to 
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fully unravel mechanistic details of toxicity. Due to these issues being common across many 
amyloid diseases, a variety of crosslinking methods have been employed to stabilize oligomeric 
intermediates so that structural and functional analysis can be performed.65–67,105 Our results have 
several implications for these strategies. First, crosslinking can alter the biophysical properties of 
oligomers, altering their exogenous interactions. Here, it was demonstrated that altering 
conformational flexibility impacts the membrane activity and toxicity of htt oligomers. This 
implies that htt membrane association plays a key role in toxicity. It could also be that the further 
aggregation of oligomers is required for toxicity, that is, the process of aggregation causes cellular 
damage rather than a discreet aggregate. Second, this impact on oligomer membrane activity 
suggests that crosslinking or otherwise interfering with conformational flexibility of oligomers 
may represent a therapeutic strategy. However, such an approach would require a crosslinking 
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4. Conclusion  
4.1. Abstract 
 Work presented here aimed to elucidate molecular mechanisms of huntingtin (htt) 
aggregation with a particular focus on the process in the presence of lipid membranes. The ultimate 
goal of such investigations to understand critical features of htt and its aggregate forms interacting 
with physiologically relevant membranes to gain insight into htt-induced toxicity in Huntington’s 
disease (HD). Ultimately, this may lead to new targets and strategies to develop potential 
therapeutics to treat HD.  
In Chapter 2, the impact of SUMOylation on htt aggregation in the presence and absence 
of lipid membranes was determined. Direct SUMOylation of Nt17 promoted an alternative 
aggregation pathway that leads to large, SDS soluble amorphous aggregates. These large 
aggregates were not membrane active.  In chapter 3, the interaction of various htt aggregate species 
was determined, and oligomers displayed the largest membrane activity. In an attempt to further 
investigate the htt oligomer/bilayer interaction, a crosslinking strategy was employed that target 
lysine residues of Nt17. While this strategy effectively stabilized oligomers, compromising the 
conformational flexibility of oligomers resulted in loss of their membrane activity and cellular 
toxicity, suggesting that targeting the membrane activity of htt oligomers may be a viable 
therapeutic strategy. Importantly, such a strategy may be applicable to other neurodegenerative 
diseases. However, there are still several gaps in our knowledge with regard to how htt interacts 
with membranes that still need to be elucidated. Here, several of these gaps, and strategies to 
approach these issues, will be discussed.   
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4.2. The role of heterogeneous htt aggregates in toxicity  
           Despite years of research in HD field, no therapies intervening in the protein-related 
pathology have been developed. The complexity of the htt aggregate landscape that results in  a 
variety of distinct aggregate species complicates structure/toxic function investigations. That is, 
heterogeneous aggregation precludes correlation of specific aggregate states with toxic event 
within cells. Numerous intermediate species with relatively fast interconversion rates lead to an 
overlap in different aggregate states of htt. It is clear that in transgenic cellular models of HD that 
htt species present in cells vary widely, not only from cell to cell, but even within individual cells. 
Tracking the fate of specific aggregate types is exceedingly difficult. Different aggregate types 
may play roles in overlapping, distinct toxic events, and the process of aggregate formation may 
potentially serve a toxic function. The heterogeneous mixture of htt species ranges from low 
molecular weight species, i.e. monomers and small multimers, to intermediately sized oligomers, 
amorphous aggregates, and fibrils that can all ultimately coalesce into to micron-sized inclusion 
bodies (Fig 4.1). While there is a general consensus that  polyQ length and protein concentration 
regulate of htt aggregation,1 various species appear to play different roles in an assortment of 
pathological mechanisms. Some aggregate species could represent toxic entities, while others may 
actually impart a protective effect.  It has been challenging to study each step independently; 
therefore, many studies focus on global cytotoxicity that may result from a conglomeration of toxic 
mechanisms. Obtaining specific structure/toxic function relationships is of fundamental 
importance for the development of therapies targeting htt aggregation. While the formation of 
intranuclear or cytoplasmic inclusion bodies precedes  behavioral deficits in a transgenic mouse 
model of HD,2 several observations suggest a poor correlation between inclusion body formation 




Fig 4.1 Atomic force microscopy images of a variety of aggregates formed by htt-exon1 proteins. (A) Htt 
exon1 can form a variety of globular, oligomeric species (purple arrows indicate oligomers ∼5 nm in 
height; green arrows indicate oligomers ∼10 nm in height). (B) Two morphologically distinct fibrils 
structures formed by exon1 (orange circles indicate thinner, smooth fibril structures; pink circles indicate 
thicker fibrils with a beaded morphology). (C) Blue circles indicate large bundles of htt exon1 fibrils. (D) 
Large, amorphous aggregates of htt exon1 are indicated by red arrows (note the color scale goes up to 50 
nm). (E) When htt exon1 aggregates on a lipid bilayer, a variety of oligomeric aggregates (blue arrows) 
associated with regions of increased membrane roughness (outlined with the green dashes lines) are 
observed. (F) When adding monomeric htt exon1 to preformed fibrils, the monomer can accumulate around 
the fibrils and form a variety of branching points (numbers indicated the same fibril at 0 and 120 min after 
exposure to monomeric htt exon1). 
Inclusion body formation may function as a coping response to toxic mutant htt by sequestering 
the diffuse htt fraction, increasing cell survival.5 Given this potential protective role of inclusion 
bodies, the pathologic importance of smaller aggregate species within the diffuse htt fraction has 
been extensively scrutinized, as evidence points to their role in initialing toxic events.6 However, 
diffuse htt fraction is occupied with a variety of nanoscales aggregates species such as small 
tetramers to large aggregates containing 1000 - 3000 molecules, including distinct oligomers and 
fibrils.6  
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 In various models and contexts, toxic function has been attributed to numerous, distinct htt 
aggregates. Initially, inclusion bodies were found to be comprised of fibril structure in post mortem 
brains of HD, as well as animal and cellular HD models.2,7,8 Mutations that promote direct 
formation of β-sheet rich fibrils enhance toxicity in cell culture and Drosophila models of HD,  
supporting the underlying amyloid structure may be key in some toxic mechanisms.9 While the 
interaction of insoluble fibrillar inclusion with proteins may be at the surface, the interaction of 
early-stage diffused aggregates of mutant htt could be multifarious with detrimental effects that 
may contribute to phenotype developments and neuronal dysfunction. Several different sized 
soluble oligomers have been postulated to be potent toxic species,10–12 and higher levels of soluble 
oligomers correlates with increased toxicity, independent of inclusion formation.11 Smaller soluble 
oligomer display abnormal interactions with over 800 cellular proteins.11 Oligomers are linked to 
ER stress12–14, mitochondrial fragmentation, and oxidative DNA damage.15 However, the transient 
nature and the heterogenicity of oligomers complicated the characterization of these species. 
Different oligomers may have different distinct roles in the formation and eventual elongation of 
fibrils. Additionally, as cellular dysfunction and toxicity likely lie in the balance between the 
various species, the mixture of monomeric/oligomeric/fibrillar aggregates and exogenous factors 
that alter aggregation are clearly of pathological significance. Identifying these cellular factors that 
regulate htt aggregation and evaluating the extent to which the mixture of 
monomeric/oligomeric/fibrillar aggregates are altered may provide valuable insight into designing 
HD therapies.  
4.3. Mechanistic-based approaches to investigate htt aggregation pathway and lipid 
membrane interaction  
 While numerous factors modify htt aggregation, the flanking sequences adjacent to the 
polyQ domain16–19 and the presence of the lipid membranes20,21 both play a critical role in 
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ultimately influencing  the aggregation process. Many naturally-occuring posttranslational 
modifications (PTMs) within the Nt17 flanking sequence alter aggregate structure and stability.22–
27 Many of these PTMs are associated with the altered toxicity,23,26 but the majority of these studies 
fail to precisely characterize the impact on diffuse htt aggregate species due to limited resolution 
of optical microscopy employed. For example, SUMOylation reduces the formation of visible 
SDS-insoluble inclusions, and enhanced htt SUMOylation in Drosophila modles increases 
neurodegeneration,26 linking diffuse htt with toxicity. With regard to this PTM, limitations due to 
the diffraction limit associated with optical techniques employed did not allow for specific 
characterization of the nanoscale aggregates species promoted by SUMOylation, raising the 
question regarding what aggregates species in the diffuse fraction are promoted by SUMOylation. 
For this reason, in chapter 2, the resulting nanoscale aggregates formed by SUMOylated htt were 
characterized morphologically and biochemically.  This study clarified the morphology and 
biophysical characteristic of nanoscale htt aggregate promoted by SUMOylaion, demonstrating 
that even when a fraction of the total htt has been SUMOylated that the aggregate species formed 
were greatly modified. In particular, SUMOylation promoted amorphous aggregates and inhibited 
fibril formation, suggesting that aggregates on the pathway to amorphous aggregation are benign 
relative to those associated with fibrillization.     
 Many common toxic mechanisms have been hypothesized to contribute to HD pathology 
(Fig 4.2).6,28–30 Many potential toxic mechanisms point to htt-exon1(46Q) disrupting of cellular 
and subcellular membranes, triggering a cascade of determinantal toxic effects.18,31 Additionally, 
concentrating htt due to subcellular localization on lipid membranes may create conditions 
nucleating aggregation, or the unique chemical environment associated with bilayers may promote 
and stabilize specific conformers involved in toxicity that would otherwise be transient. While htt 
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clearly associates with lipids,18,32,33 little is known about how htt aggregation state influences these 
interactions. 
 
Fig 4.2 Toxic gain of function pathogenic mechanisms associated with polyQ diseases. 
Experiments presented in Chapter 3 demonstrated that oligomers enhance the membrane activity 
of htt compared to monomers, and that fibrils displayed minimal interactions with membranes. 
This suggests that oligomers mediate membrane-associated htt toxic mechanisms. Chemically 
stabilizing oligomers, however, abolishes their membrane activity and reduces htt toxicity, 
implying that conformational flexibility within oligomers may play a crucial role. As such, these 
results revealed that targeting the membrane activity of htt is a viable therapeutic strategy.   
 While the findings here support a role for soluble oligomers in HD pathology, crosslinking 
strategies have been broadly applied in attempts to elucidate the structure/toxic function properties 
of several amyloid-based oligomers. However, care must be taken, as Chapter 3 demonstrates that 
these strategies can profoundly alter the biological activity of oligomers. In the past DFDNB 
crosslinking technique has been used to stabilize Ab oligomers, and stabilized Ab oligomers 
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increased memory dysfunction in mice.34 While the increased pathogeny of Ab crosslinked 
oligomers is inconsistent with our observation, the disagreement may result from difference 
between the size distribution of crosslinked oligomers observed in each study. The stabilized htt 
oligomers were a more homogenous population compared to their crosslinked Ab counterparts. In 
Aβ, oligomer of different sizes are known to have various toxic potency.35 Another factor may be 
the innate toxicity of the DFDNB crosslinker itself.  
Alternative strategies to stabilize htt oligomers may not alter their biological activity and 
may be considered for future structure/toxic function analysis. Other crosslinking strategies have 
stabilized Ab oligomers without impairing toxicity.34,36,37 For example, crosslinking Ab oligomers 
with glutaraldehyde resulted in a homogenous, stable oligomer population that could be purified 
by size-exclusion chromatography. This treatment did not cause random non-specific protein 
crosslinking of oligomers and, more importantly, did not alter the proteasome impairment activity 
of these oligomers compared to non-crosslinked Ab. As protein context, i.e. flanking sequences, 
are known to alter htt aggregation, the addition of exogenous tags could be used to effectively 
stabilize htt oligomers, but care must be taken as some tags are known to alter toxicity of htt in 
cellular models.38,39 Targeting the oligomer-promoting Nt17 region attached to a pathogenic polyQ 
with another Nt17 peptide inhibits fibrillization and stabilizes oligomers.19,40 Such a strategy would 
not alter the conformational flexibility of the htt oligomers. Free polyP peptides added to mutant 
htt also stabilize htt oligomers, representing another viable option . Nevertheless, unraveling 
specific structure/toxic function of htt aggregates will require the ability to control the aggregation 
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